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Caveolin-1 (Cav-1) is a membrane associated scaffolding protein that regulates a myriad 
of signaling molecules.  It has been implicated as both a tumor suppressor and promoter.  Here, 
we examine the protein’s link to senescence and cancer, and identify a novel pathway through 
which Cav-1 mediates stress induced premature senescence (SIPS) through p53 activation. 
Oxidative stress triggers p38MAPK , which activates the transcription factor Sp1.  Sp1 binds to 
two GC-rich regions in the caveolin-1 promoter up-regulating the protein.  Cav-1 binds to p53’s 
negative regulator, MDM2, sequestering the E3 ligase to allow p53 to become active.  p53 
activates its downstream targets, such as p21WAF/CIP1, which initiates SIPS.  This pathway is 
dysfunctional in many cancers that have a downregulated Cav-1 gene. The effects of oxidative 
stress in Cav-1 null backgrounds were examined.  Breast cancer cells that do not express Cav-1 
cannot undergo oxidatively induced SIPS.  However, upon re-expression of Cav-1, the SIPS 
phenotype is restored.  Utilization of Cav-1 knockout mouse embryonic fibroblasts show that 
without Cav-1 to sequester MDM2, allowing for the upregulation of p53 leading to SIPS, cells 
continued to proliferate. These results distinguish Cav-1 as a molecular “senescence switch,” 
because in its absence oxidative SIPS does not occur, but in its presence it does.  This effect is 
also not specific to a particular cell type; data supports Cav-1 as a molecular switch in epithelial 
and fibroblast cell lines. Finally, senescence is known to have antagonistic pleiotropic effects on 
an organism.  That is, cell senescence is beneficial for younger organisms, as it prevents the 
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proliferation of mutated genomes through growth arrest.  However, an accumulation of senescent 
cells can lead to aging and become detrimental.  Cav-1’s role in the antagonistic pleiotropic 
effects of senescent fibroblasts on neoplastic epithelial cells is also explored.  Data shows that 
senescence of fibroblasts depends upon Cav-1 sequestering MDM2, which activates p53 and 
induces SIPS.  These fibroblasts can secrete factors that make it advantageous for NIH 3T3 
RasG12V transformed fibroblasts and MDA-MB-231 breast cancer epithelial cells to proliferate in 
vitro and in vivo.  Hence, we propose that the Cav-1 gene functions with antagonistic pleiotropy. 
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1.0  INTRODUCTION 
In the United States of America and in most developed countries, the population is aging.  The 
United States census of 2000 shows the 50-54 year age group has experienced the largest 
percentage of growth out of all of the 5-year age groups, followed by the 45-49 year old group 
(www.census.gov).  These two groups consist of the “baby boomers,” or those born following 
World War II.  The aging population is a major concern of the healthcare system as aging has 
many social, psychological and physiological ramifications.  Of relevance to this dissertation, is 
aging is linked to cancer; sixty percent of all cancers and 70% of mortalities related to the 
disease occur in those 65 years and older (Yancik and Ries 2000). 
Aging and cancer are by definition opposites.  Aging is the cumulative effect of a 
decrease in proliferation of cells whereas cancer is the abnormal increase in proliferation of cells.  
Likewise, these two conditions share many of the same signaling pathways. I am interested in 
studying signaling molecules aging and cancer have in common, observing how their regulation 
is controlled to gain insight into the mechanisms of how aging and cancer relate.  This 
dissertation focuses on the Cav-1 protein and how it regulates aging at the cellular level, defined 
as senescence.  Cav-1 is a protein that is related to both senescence and cancer and is therefore a 
critical link with potential for therapeutic purposes. 
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1.1 SENESCENCE 
In the 1960’s Leonard Hayflick discovered cells in culture were not immortal, but would 
stop di
s derived from it (Stanley, Pye et al. 1975; Rohme 1981).  Additional evidence 
over th
an increase of senescent cells with age as noted in primate skin (Herbig, Ferreira et al. 2006; 
viding after a certain number of cell divisions (Hayflick 1965). This started to shed light 
on the mechanisms of the aging process.  It was determined this replicative limit was partially 
due to DNA damage and telomere shorting.  Extrapolation to the organismal level predicts 
limited cell division would lead to a non-renewal of tissues and thus aging.  ‘Senescence’ is a 
term derived from the Latin senex meaning to advance in age.  It is broadly used to describe the 
cellular growth arrest, which Hayflick first described. Cellular senescence is triggered through 
intrinsic (e.g. telomere shorting from replication, and metabolic reactive oxygen species (ROS) 
production) and extrinsic (e.g. chemical toxicity or irradiation) stimuli.  Cellular senescence is 
characterized by changes towards larger and flatter cell morphology, cessation of DNA 
replication, positive staining for senescence associated β-galactosidase (Cho, Ryu et al. 2003) 
and expression of certain cellular proteins such as p16INK4a, p53 and p21WAF/CIP1, which lead to 
growth arrest (Collado and Serrano 2006).   
Despite current dogma, there is still a debate as to whether senescence was an in vitro 
phenomena or whether it played a role in organismal aging.  As reviewed by Chen et al. (Chen, 
Hales et al. 2007), many recent findings show a relationship between cellular senescence and 
aging.  For instance, an animal’s known longevity correlates with the in vitro replicative 
potential of cell
e past 30 years demonstrated increased replicative senescence in vitro from cells taken 
from patients with Werner syndrome or other prematurely aging donors (Martin, Sprague et al. 
1970; Martin 1982; Fujiwara, Kano et al. 1985; Davis, Wyllie et al. 2007).  In vivo, there is also 
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Jeyapalan, Ferreira et al. 2007), human vascular tissue (Minamino, Miyauchi et al. 2004; 
Matthews, Gorenne et al. 2006; Minamino and Komuro 2007), and rodent and human kidneys 
(Melk, Kittikowit et al. 2003; Krishnamurthy, Torrice et al. 2004; Melk, Schmidt et al. 2004).  
Recent data gives evidence of in vivo SIPS.  For instance, nephropathies, postoperative 
stress, and inflammation cause premature senescence of renal cells in the kidney (Famulski and 
Halloran 2005).  Additionally, inflammation of chronic wounds causes SIPS in fibroblasts 
(Harding, Moore et al. 2005), and Laser-Assisted In Situ Keratomileusis (LASIK) causes in vivo 
SIPS of the corneal keratocytes (Dawson, O'Brien et al. 2006). SIPS is triggered when oxidative 
stresses cause DNA damage, or when there is oncogenic activation, as with RasG12V, leading to 
too much proliferation in primary cell lines (Sebastian, Malik et al. 2005). Common sources of 
oxidative stresses include hydrogen peroxide, UV exposure, bleomycin, tert-butyl-
hydroperoxide, ethanol, psoralen plus UVA or hyperoxia (Rodemann, Bayreuther et al. 1989; 
Toussaint, Houbion et al. 1992; Chen and Ames 1994; von Zglinicki, Saretzki et al. 1995; Robles 
and Adami 1998; Toussaint, Medrano et al. 2000; Frippiat, Chen et al. 2001; Dumont, Chainiaux 
et al. 2002; Borlon, Debacq-Chainiaux et al. 2007).   The hyroxyl radical (•OH) generated from 
the reaction of hydrogen peroxide with transition metals induces DNA damage such as single 
stranded breaks (SSBs) (McDonald, Pan et al. 1993; Lee, Madden et al. 1996; Chen, Nishida et 
al. 2003) and double strand breaks (DSBs) (Iliakis, Pantelias et al. 1992; Dahm-Daphi, Sass et al. 
2000).  DNA breaks stimulate DNA repair mechanisms involving the p53 protein, which can 
activate SIPS.  
SIPS is triggered by cell signaling pathways that stimulate cell cycle arrest. Normally, 
SIPS is initiated by an exogenous DNA stressor, which causes SSBs or DSBs in the DNA.  DNA 
repair proteins such as poly ADP-ribose polymerase-1 (PARP1) recognize these breaks.  PARP-
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1 is a nuclear protein that post-translationally modifies histones and DNA repair proteins 
resulting in chromatin relaxation and the binding of other proteins (D'Amours, Desnoyers et al. 
1999; Kim, Zhang et al. 2005; Beneke and Burkle 2007).  With assistance from Rad17, a DNA 
dama eterotrimeric 
complex is sim aged DNA 
(Kostrub, K oos-Mattjus et al. 2001; 
Shiomi, Shi
, regulating cell cycle 
odimer 
comp  checkpoint proteins 
(Kastan and Lim M2.  ATM’s 
regulation of these proteins is HK2 on threonine 68, activating 
man et 
increases its tum ates MDM2 on serine 
directly act 
m et al. 1998) 
causing an increase in p  the above mechanisms 
CDC25A inhibit CDKs.  The inhibited CDKs can no longer phorsphorylate the Rb protein.  
Therefore, hypophosphorylated Rb can bind to its downstream target transcription factor E2F 
ge signal is propagated by the 9-1-1 signal or Rad9-Rad1-Hus1.  This h
ilar to proliferating cell nuclear antigen (PCNA) which binds to dam
nudsen et al. 1998; Venclovas and Thelen 2000; Burtelow, R
nozaki et al. 2002).  In conjunction, the serine/threonine protein kinase Ataxia 
Telangiectasia Mutated (ATM) is activated and phosphorylates proteins
arrest.  ATM autophosphorylates, resulting in dissociation from its inactive hom
lexes (Bakkenist and Kastan 2003) and is free to phosphorylate G1
 2000) such as p53, histone H2AX, CHK2, CHK1 and MD
 linked:  ATM phosphorylates C
CHK2, which phosphorylates p53 on serine 20 (Ahn, Schwarz et al. 2000; Matsuoka, Rot
al. 2000).  This decreases the association between p53 and MDM2, which stabilizes p53 and 
or suppressor capabilities.  Additionally, ATM phosphoryl
395, which decreases its affinity for p53 (Maya, Balass et al. 2001).  ATM can also 
on p53 by phosphorylating serine 15 (Banin, Moyal et al. 1998; Canman, Li
53 activity.  The increase in p53 activity from
causes p53 to increase transcription of its downstream target p21WAF1/CIP1.  As a cyclin dependent 
kinase inhibitor, p21WAF1/CIP1 inhibits cyclinE/CDK2.  This blocks the cell in G1 by inhibiting 
entry into S phase (Kastan, Onyekwere et al. 1991).  Additionally, the activation of p16INKa and 
 21 
and inhibit the protein’s activity.  E2F up-regulates genes responsible for continuation 
throughout the cell cycle.  With E2F activity blocked, the cell cannot proliferate and is growth 
arrested.   
 
Figure 1.  Signal transduction pathway leading to senescence.  Cellular stressors lead to DNA damage resulting 
in BER, SSBs, and DSBs.  This recruits DNA damage sensing proteins.  Depending upon whether the DNA is 
repairable, the cell induces a signaling cascade resulting in transient growth arrest, apoptosis, or as illustrated here, 
senescence (Campisi and d'Adda di Fagagna 2007; Bertram and Hass 2008). 
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The field of biomedical science is now uncovering many more SIPS occurrences in vivo.  
LASIK eye surgery trigger he cornea (Dawson, O'Brien et al. 
2006).  Inflammatory factors of chronic wounds trigger SIPS in surrounding fibroblasts, which 
of the wounds to heal (Harding, Moore et al. 2005).  Senescence in kidney 
epithelial cells may affect organ transplantation success (Famulski and Halloran 2005). 
er their surrounding 
microenvironment to induce preneoplastic cells to become cancerous by secreting matrix 
me a oproteinases and cytokines (Liu and Hornsby 2007).  Additionally, the age-induced 
accumulation of senescent cells disrupts normal tissue architecture and function (Campisi 2005), 
and senescent cells no longer proliferate causing tissues to lose the capability to adequately 
repair (Harding, Moore et al. 2005). 
s senescence in keratocytes of t
affect the ability 
Treatments for certain diseases may cause early onset of age-related issues, as evidenced by the 
observation that PUVA treatment causes aged skin in psoriasis patients (Sator, Schmidt et al. 
2002).  In another example, antiretroviral thymidine analogues were linked to premature aging of 
HIV patients taking the drug (Caron, Auclairt et al. 2008).  Knowing the mechanisms responsible 
for SIPS will aid in designing treatments to minimize its detrimental side effects.  For instance, 
senescent cells are located at the sites of age-related diseases such as atherosclerotic lesions, skin 
ulcers, arthritic joints, benign and preneoplastic hyperproliferative lesions in prostate and liver 
(Campisi 2005).  The mechanisms leading to cellular senescence in vivo will lay the foundation 
for improving public health in our ageing population as age-related diseases begin to increase. 
It is critical to determine how SIPS is involved in organismal ageing as research has 
indicated senescent cells have positive and negative effects on an organism (Campisi 2005).  The 
fact that senescent cells no longer undergo mitosis may indicate senescence is a tumor suppressor 
(Pelicci 2004; Schmitt 2007).  However, senescent cells can alt
t ll
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 1.2 CAVEOLIN-1 
1.2.1 Caveolae 
Caveolae are membrane invaginations found in fibroblasts, adipocytes, endothelial cells, type I 
pneumocytes, epithelial cells, and smooth/striated muscle cells (Razani, Schlegel et al. 2000) 
(Capozza, Cohen et al. 2005) (Hagiwara, Nishina et al. 2002) (Razani, Woodman et al. 2002). 
Caveolae are characterized as 50-100 nm flask shaped microdomains at the plasma membrane 
and in plasmalemmal vesicles (Hagiwara, Nishina et al. 2002) (Razani, Wang et al. 2002).  They 
are classified as a type of lipid raft containing cholesterol, sphi
 
ngolipids and glycosyl 
phosphatidylinositol anchored proteins (Capozza, Cohen et al. 2005) (Razani, Woodman et al. 
the cell such as: cellular metabolism, vesicle 
trafficking, signal transduction, cholesterol homeostasis, endothelial transcytosis, calcium uptake 
2002).  Caveolae have numerous functions in 
and tumor suppression (Capozza, Cohen et al. 2005) (Hagiwara, Nishina et al. 2002) (Razani, 
Woodman et al. 2002).  In muscle cells, the formation and opening of transverse T-tubules are 
associated with caveolae (Hagiwara, Nishina et al. 2002). The caveolin proteins are markers of 
caveolae (Williams, Medina et al. 2004) (Razani, Woodman et al. 2002).   
1.2.2 Caveolin family of proteins 
The three isoforms of caveolin are highly conserved across species with molecular weights 
averaging 18-24 kDa (Jain-Hua Chen 2004) (Razani, Woodman et al. 2002). Caveolins act as 
scaffolding proteins to compartmentalize signaling molecules within the cell (Razani, Schlegel et 
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al. 2000).  The three products of the caveolin genes are Caveolin-1 (Cav-1), Caveolin-2 (Cav-2) 
and Caveolin -3 (Cav-3).  Cav-1 and 2 are mapped to the 7q31.1 human chromosome and 
caveolin-3 is found on 3p25 (Williams, Medina et al. 2004). Cav-1 and 2 are co-expressed in 
many cell types and can form hetero-oligomers with each other, whereas Cav-3 is specific to 
muscle cells (Razani, Schlegel et al. 2000) (Hagiwara, Nishina et al. 2002).  Thus far only 
arterial and bladder smooth muscle cells are known to co-express all three caveolin isoforms 
(Segal, Brett et al. 1999) (Woodman, Cheung et al. 2004).  While the caveolin proteins make up 
caveolae, recent evidence indicates they are not sufficient for the organelle’s formation.  PTRF-
Cavin associates with mature caveolae and is necessary to mobilize Cav-1 into immobile 
caveolae.  Without PTRF-Cavin, Cav-1 still associates with lipid rafts on a flat plasma 
membrane surface (Chadda and Mayor 2008; Hill, Bastiani et al. 2008). 
1.2.3 Cav-1 post-translational modifications 
Cav-1 is a 22-kDa protein consisting of 178 amino acid residues.  Two isoforms are known to 
exist in nature: α-caveolin (the full length protein), and β-caveolin (which contains residues 32-
178) (Li, Seitz et al. 1996).  Cav-1 is inserted into the plasma membrane by a hairpin 
intramembrane domain with the N and C terminals facing the cytosol (Goetz, Lajoie et al. 2008).  
The protein can undergo many post-translational modifications.  Palmitoylation of cysteines 133, 
localization to caveolae (Dietzen, Hastings et al. 
1995), but is essential for cholesterol binding and transport complex formation (Uittenbogaard 
143 and 156 is not necessary for the protein’s 
and Smart 2000).   Tyrosine kinases Src, c-Abl and Fyn can phosphorylate tyrosine 14 of the 
Cav-1 protein (Li, Seitz et al. 1996; Sanguinetti, Cao et al. 2003; Sanguinetti and Mastick 2003).  
Exogenous cellular stressors activate Y14 phosphorylation on Cav-1 through a mechanism 
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involving p38MAPK and c-Src.  Phosphorylated Cav-1 is localized to focal adhesions where 
various tyrosine kinase signaling takes place (Lee, Volonte et al. 2000; Volonte, Galbiati et al. 
2000). Phosphorylated Cav-1 effects integrin-regulated membrane domain internalization (del 
Pozo, Balasubramanian et al. 2005), and epithelial growth factor mediated formation of caveolae 
in epithelial cells (Orlichenko, Huang et al. 2006).  Phospho-Cav-1 is also a docking site for the 
Src Homology 2 (SH2) binding domain-containing proteins such as Growth Factor Receptor-
Bound 7 (Grb7) (Lee, Volonte et al. 2000) and C-terminal Src Kinase (Csk).  Additionally, 
tumor necrosis factor-alpha receptor-associated factor 2 (TRAF2)’s binding affinity for Cav-1 
increases with Y14 phosphorylation (Cao, Courchesne et al. 2002).  However, the mouse 
studies recognizes 
experime
al. 2007).  P
horylation 
of serine 80 llular sterol 
or 
prom illiams and 
Lisanti 2005).
1.2.4 
 
without caveolae and in non-caveolar regions (Head and Insel 2007).  Recently it was found in 
monoclonal anti-PY14 Cav-1 antibody used in many of the above 
phosphocaveolin-1 in immunoblot analyses, but the labeling obtained in immunostaining 
nts is questionable because the antibody cross reacts with paxillin (Hill, Scherbakov et 
hosphorylation at serine 80 allows caveolin-1 to become a soluble secreted protein 
(Schlegel, Arvan et al. 2001).  Inhibition of protein kinase C causes decreased phosp
 and increased sterol binding to Cav-1, which lead to a decrease in ce
efflux (Fielding, Chau et al. 2004).  Phosphorylation of Cav-1 is also associated with its tum
oting capabilities as it causes interaction with growth stimulatory proteins (W
 
Cav-1 in non-caveolae environments 
Cav-1 trafficking is not limited to embedding into the plasma membrane and incorporating into 
caveolae.  Cav-1 also has cellular functions outside of the caveolae, as it is expressed in cells
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the cytoplasm and nucleus after oxidative stress (Chretien, Piront et al. 2008).  Localization o
Cav-1 is cell type specific: in skeletal muscle cells and keratinocytes it is located in 
it is found in mitochondria.  This indicates novel pathways for Cav-1 to mediate lipid trafficking 
to multiple cellular compartments (Li, Liu et al. 2001).  Cav-1 is also a soluble secreted pr
as it is released by pancreatic explants and in the presence of gastrointestinal hormone 
stimula
f 
the 
cytoplasm, in endocrine and exocrine cells it is found in secretory vesicles, and in epithelial cells 
otein 
tion it is secreted in pancreatic juice (Thomas, Krzykowski et al. 2004).  Additionally, 
Cav-1 secretion by prostate cancer cells is correlated with proangiogenic effects, which may lead 
to the metastases of these tumors (Tahir, Yang et al. 2001; Tahir, Yang et al. 2008). 
 
Figure 2.  Schematic of the Cav-1 protein.  The Cav-1 protein is a 22-kDa protein with 178 amino acid residues.  
The N and C terminals face the cytosol and a hairpin loop embeds the protein in the plasma membrane. 
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Palmitoylation of cysteines 133, 143 and 156 help to anchor the protein.  Cav-1 has four major domains consisting 
of the 1) oligomerization domain (amino acids 61-101) which is needed to form monomers and heteromers with 
and 4) the C-terminal attachment domain (135-150).  Post-translational phosphorylation can occur at tyrosine 14 and 
serine 80. Po
Caveolin-2, 2) the Caveolin Scaffolding Domain (CSD) binds to many signaling molecules, 3) the transmembrane 
domain (amino acids 102-134) which consists of the hairpin loop to associate the protein with the plasma membrane 
int mutation of proline 132 to leucine in the transmembrane domain has been identified in breast 
cancers in humans and causes a dominant negative protein (Razani, Woodman et al. 2002; Shatz and Liscovitch 
2008). 
1.2.5 Cav-1 and the signaling hypothesis 
Cav-1 interacts with a number of diverse signaling molecules. Cav-1 can inhibit H-Ras (Song, Li 
et al. 1996), Src-family tyrosine kinases (Shenoy-Scaria, Dietzen et al. 1994; Li, Couet et al. 
1996), G protein α subunits (Li, Okamoto et al. 1995; Schnitzer, McIntosh et al. 1995), 
endothelial nitric oxide synthase (Feron, Belhassen et al. 1996; Liu, Garcia-Cardena et al. 1996; 
Ju, Zou et al. 1997), epidermal growth factor receptor (Mineo, James et al. 1996; Couet, 
Sargiacomo et al. 1997; Segal, Brett et al. 1999), Neu (c-erbB2) (Engelman, Lee et al. 1998), 
protein kinase A (Razani and Lisanti 2001), protein kinase C platelet derived growth factor 
receptor (Smart, Foster et al. 1993; Yamamoto, Toya et al. 1999), tumor growth factor β receptor 
(Razani, Zhang et al. 2001), and neurotrophin receptor (Bilderback, Gazula et al. 1999). There 
are a few instances when binding to Cav-1 causes activation of a signaling molecule such as the 
estrogen and insulin receptors (Yamamoto, Toya et al. 1998; Schlegel, Wang et al. 2001).  
Furthermore, Cav-1 mediates cellular functions such as regulating endocytosis of α5β1 integrins 
and fibronectin (Shi and Sottile 2008).  Many of the proteins interacting with Cav-1 bind to the 
stretch of amino acids referred to as the Caveolin Scaffolding Domain (CSD) (Couet, Li. et al. 
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1997). The CSD lies within amino acid resides 82-101: DGIWKASFTTFTVTKYWFYR.  
These findings have led to the caveolin signaling hypothesis, which states that caveolins serve as 
scaffolding domains to modulate cell signaling molecules (Lisanti, Scherer et al. 1994), as 
supported by caveolins organizing “preassembled signaling complexes” (Okamoto,
 
 Schlegel et 
al. 1998
te (TRAMP) mice crossed to wildtype or knockout Cav-1 mice show in the absence 
of Cav-1, there is delayed onset of highly invasive prostate cancer and metastatic disease 
merous studies in vitro and in vivo show Cav-1 as a 
prognostic marker for the disease.  Cav-1 is a predictor of biochemical failure defined by a 
). 
1.2.6 Cav-1 and tumor promotion 
The Cav-1 protein is continually studied in the pathogenesis of malignancy.  Many cancer cell 
lines have a high expression of the protein (Lavie, Fiucci et al. 1998; Nasu, Timme et al. 1998; 
Hurlstone, Reid et al. 1999; Davidson, Nesland et al. 2001).  In particular, Cav-1 is over-
expressed in prostate cancer and its levels are elevated in metastatic prostate cancer cell lines 
(Shatz and Liscovitch 2008).  Additionally, Cav-1 has been linked to a predisposition of prostate 
cancer in vivo (Haeusler, Hoegel et al. 2005).  Research using transgenic adenocarcinoma of 
mouse prosta
(Williams, Hassan et al. 2005).  Nu
prostate specific antigen [PSA]> 0.2 ng/mL (Goto, Nguyen et al. 2008).  Additionally, high pre-
operative levels of serum Cav-1 is a predictor for cancer reoccurrence (Tahir, Frolov et al. 2006), 
and Cav-1 secreted by prostate cancer cells, is taken up by endothelial cells where it triggers the 
proangiogenic phosphoinositide 3 kinase(PI3K)-protein kinase B (Akt)-endothelial nitric oxide 
synthase (eNOS) signaling pathway leading to tubulin formation, cell migration and nitric oxide 
production (Tahir, Yang et al. 2008).  Additionally, over-expression of Cav-1 is associated with 
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prostate cancer and aggressive PSA reoccurrence in patients treated with radical prostatectomy 
(Karam, Lotan et al. 2007).  Finally, tumor promoter, fatty acid synthase (FASN), is upregulated 
during prostate cancer progression and is linked to metastatic disease.  Cav-1 expression is 
necessary to elevate levels of FASN in TRAMP mice (Di Vizio, Sotgia et al. 2007). 
The upregulation of Cav-1 is most thoroughly documented in prostate cancer, but it 
occurs in other types of cancers as well.  For instance, in ovarian carcinoma cells Cav-1 is 
localize
ssociated with cell proliferation. Cyclin D is a 
regulat
ung 
et al. 2003).   Furthermore, fibroblasts transformed by oncogenes such as RasG12V and c-Abl or 
d to inactive chromatin and can bind to genes involved in proliferation (Sanna, Miotti et 
al. 2007).  Additionally, in inflammatory breast cancer, a very aggressive form of the disease, 
Cav-1 is over-expressed and its gene promoter is hypomethylated (Van den Eynden, Van Laere 
et al. 2006).  In patients with pleomorphic carcinoma of the lung, Cav-1 has high expression and 
is correlated with decreased disease-free and survival rates (Moon, Lee et al. 2005).  In non-
small cell lung cancer (NSCLC), Cav-1 expression is linked with tumor stage and lymph node 
metastasis (Yu, Wei et al. 2006).  Furthermore, in NSCLC Cav-1’s expression is associated with 
drug resistance and poor prognosis in patients treated with gemcitabine chemotherapy (Ho, Kuo 
et al. 2008). 
1.2.7 Cav-1 as a tumor suppressor 
Even though Cav-1 is linked to tumor promotion it is also hypothesized to be a tumor suppressor 
because the protein inhibits signaling molecules a
ory unit of cyclin dependent kinases (CDKs) necessary for progression through the cell 
cycle.  Over-expression of Cav-1 causes transcriptional repression of cyclin-D (Hulit, Bash et al. 
2000), and knocking out caveolin-1 causes upregulation of cyclin D1 levels (Williams, Che
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the hum
 down-regulated  (Razani, et al 2002 and van Deurs, et al. 2003).  
Continu
iatchenko et al. 2001), and human colon tumors (Bender, Reymond et al. 2000).  
Cav-1’s ties with cancer also extend to p53, which is known to be non-functioning in most 
53 by viral oncoproteins also causes a decrease in Cav-1 
expression.  Additionally, p53 null mice -/- exhibit a decreased Cav-1 expression (Lee, Reimer et 
al. 199
an papilloma virus have a downregulated Cav-1 gene (Koleske, Baltimore et al. 1995; 
Razani, Altschuler et al. 2000). When Cav-1 was re-expressed in these cells it rescued the cells 
from the transformed phenotype (Engelman, Wycoff et al. 1997; Razani, Altschuler et al. 2000). 
Recently, numerous oncogenes have been shown to down regulate Cav-1 including but not 
limited to: c-Myc, HPV E6, v-Abl, Bcr-Abl, H-RasG12V, v-Src, and Neu/Erb2, (reviewed 
by(Williams and Lisanti 2005). 
The caveolin-1 gene is localized at chromosome 7q31.1, a region deleted in many human 
cancers where caveolin-1 is
ing research illustrates a growing list of cancers in which Cav-1 is downregulated by 
promoter methylation, mutation, or yet to be discovered mechanisms.  For instance, 
downregulation of Cav-1 has been reported for: osteoblast transformation and osteosarcoma 
progression (Cantiani, Manara et al. 2007), mucoepidermoid carcinoma (Shi, Chen et al. 2007), 
hepatocellular carcinoma (Hirasawa, Arai et al. 2006), invasive ductal carcinoma of the breast 
(Park, Kim et al. 2005), gastric carcinogenesis (Gao, Sun et al. 2005), small cell lung cancers 
(Wiechen, Diatchenko et al. 2001; Sunaga, Miyajima et al. 2004) human ovarian carcinoma 
(Wiechen, D
cancers. Downregulation of p
8; Razani, Altschuler et al. 2000).  
In keeping with its role as a potential tumor suppressor, Cav-1 is up-regulated during cell 
differentiation.  There is high expression of the protein in terminally differentiated cells such as 
adipocytes, pneumocytes, chondrocytes and smooth muscle cells (Goetz, Lajoie et al. 2008). 
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The creation of Cav-1 knockout mice has also led to implications of Cav-1’s tumor 
suppressor capabilities.  The skin of the Cav-1 null-/- mice is more susceptible to tumors from 
carcinogenic treatment than the skin of wildtype mice is (Capozza, Williams et al. 2003). 
Embryonic fibroblasts derived from Cav-1 knockout mice are more sensitive to oncogenic 
transformation.  Once transformed they over-express cyclin D1 and express hyperactive ERK 
1/2, adding to their in vivo tumorigenesis potential (Williams, Lee et al. 2004).  Interestingly, 
Cav-1 is known to inhibit ERK1/2 activation in vitro and in vivo (Engelman, Chu et al. 1998; 
Zhang, Razani et al. 2000). 
Studies in mice also indicate that Cav-1 acts as a tumor suppressor.  When the Cav-1 null 
mice have much more 
aggressive tumors than those in the Cav-1 wildtype mice.  This is illustrated by crossing Cav-1-/- 
mice are bred into mice with cancer-prone backgrounds, the resulting 
mice with MMTV-PyMT (mouse mammary tumor virus-polyoma middle T antigen) mice.  The 
mice were followed for 14 weeks and the study demonstrated mice with the Cav-1 null 
background had accelerated onset of mammary tumors, increased tumor burden and more 
metastatic lung cancer compared to those with a wildtype Cav-1 background (Williams, Medina 
et al. 2004). 
1.2.8 Cav-1 and senescence 
Senescence is tumor suppressing for cells undergoing permanent growth arrest.  Cav-1, in 
keeping with its tumor suppressor properties, is involved in the senescence and aging process.  
Cav-1 plays a role in aging as the protein’s expression increases in aged tissues (Cho, Ryu et al. 
2003). While down regulation of Cav-1 is linked to cancer, there is also evidence that high levels 
of Cav-1 are linked to cell senescence.  Over-expression of Cav-1 can arrest growth in fibroblasts 
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through a p53/p21 dependent mechanism (Galbiati, Volonte et al. 2001). The senescent 
phenotype is reversable by reducing Cav-1 expression with siRNA (Cho, Ryu et al. 2003).  
Likewise, mouse embryonic fibroblasts over-expressing Cav-1 have increased senescence 
associated-β-galactosidase activity, p53 activity and p21 expression.  Oxidative stress, such as 
subcytotoxic doses of hydrogen peroxide or UV irradiation upregulates Cav-1 along with p53 
and p21 resulting in SIPS (Volonte, Zhang et al. 2002). Thus, data from our laboratory and 
others distinguish the protein Cav-1 as a key mediator of SIPS in fibroblasts.  How Cav-1 is 
mediating p53 activation and subsequent SIPS is not known. 
1.2.9 Cav-1 and its dual roles as a tumor suppressor and promoter 
There is solid evidence indicating Cav-1 acts as a tumor promoter and also a tumor suppressor.  
There are explanations for the protein’s dual activities; post-translational modifications or 
mutations in the protein can disrupt Cav-1’s tumor suppressing mechanisms and render it a 
tumor promoter (Williams and Lisanti 2005).    First, Cav-1 phosphorylation on tyrosine 14 
recruits c-Src/Grb7.  Phosphorylated Tyr14 bound to Grb7 enriches anchorage independent 
growth and EGF stimulated cell migration.  The residue is also constitutively active in v-Src and 
v-Abl transformed cells.  Tyr14 can also be transiently phosphorylated by growth factor 
stimulation.  Phosphorylated Cav-1 is localized to focal adhesions where much of the cell’s 
tyrosine kinase cascades occur (Lee, Volonte et al. 2000; Lee, Volonte' et al. 2000; Lee, 
Woodman et al. 2001).  Phosphorylation of a different residue, Ser80, converts Cav-1 to a 
soluble secreted form (Schlegel, Arvan et al. 2001; Liu, Rudick et al. 2002).  Secretion of the 
protein may deplete the intracellular stores, thus decreasing the protein levels of the environment 
in which it can act as a tumor suppressor.  Additionally, as the protein is secreted it may possess 
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different tumor promoting functions.  For example, Cav-1 is secreted by androgen-insensitive 
human prostate cells and directly stimulates prostate and tumor cell growth/ survival while also 
 examined 
for the m , it causes 
transform
e breast 
cancer tum α 
 
ntiated 
ion 
where it can act as a tumor suppressor for the cell (Goetz, Lajoie et al. 2008).  However, 
oncogenes can downregulate Cav-1 early in this transformation, causing excessive cellular 
 resulting in hyperplasia and preneoplastic lesions.  These Cav-1 null cells are more 
otherapy and are thus present in low-grade cancers.  Cellular stress is also 
known to upregulate Cav-1.  Continuation of genetic changes allows the cancer cells to adapt and 
acquire metastatic abilities.  Once this occurs, high levels of Cav-1 have a protective effect 
against chemotherapeutics and make cells resistant to apoptosis.  The selective pressure of the 
chemotherapeutics drive the cellular population towards these more resistant cells, creating an 
invasive and multidrug resistant tumor (Liu, Oh et al. 1997; Ravid, Maor et al. 2006; Goetz, 
exhibiting proangiogenic activities in prostate cancer (Tahir, Yang et al. 2001; Tahir, Yang et al. 
2008).  Lastly, a Pro132Leu mutation in the Cav-1 gene is in 16% of primary tumors
utation.  When Cav-1 containing this mutation is expressed in vitro
ation of cells by acting as a dominant negative mutant (Hayashi, Matsuda et al. 2001; 
Lee, Park et al. 2002).  Furthermore, screening of estrogen receptor alpha (ERα) positiv
ors for the mutation identified 19% as having the Pro132Leu mutation where ER
negative tumors did not. This study also found other mutations in the Cav-1 protein raising the 
occurrence of Cav-1 mutations in this tumor type to 35% (Li, Sotgia et al. 2006). 
In an attempt to explain how Cav-1 is downregulated in some cancers and upregulated in
others, Liscovitch hypothesizes there are changes in expression as transformation progresses 
(Shatz and Liscovitch 2008). Liscovitch observes Cav-1 expression is low in undiffere
epithelial cells, allowing for proliferation, and the protein is upregulated upon differentiat
proliferation
susceptible to chem
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Lajoie et al. 2008). This is one reason why aggressive cancers may exhibit high Cav-1 
expression. 
 
Figure 3.  Schematic illustrating the changing Cav-1 expression in tumor development.  Cav-1 is upregulated 
during differentiation, where it downregulates mitotic signaling and restrains tumor promotion.  However, with time 
and progression of transformation, the protein is downregulated in proliferating cells and the average Cav-1 
expression in a tumor decreases.  Cellular stress upregulates Cav-1, and as stress selects for metastatic and drug 
Liscovitch 2008).   
 
 
 
resistant cells, the overall expression of Cav-1 in the tumor increases at later stages of the disease (Shatz and 
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2.0 MATERIALS AND METHODS 
2.1 MATERIALS 
Cell lines for this work, NIH 3T3 fibroblasts, WI-38 fibroblasts, MDA-MB231 (a gracious gift 
from Julie Eiseman), and Ras  were purchased from ATCC (Manassas, VA).  Mouse 
embryonic fibroblasts were derived from mice in our laboratory’s breeding colony.  Cellular 
media (DMEM and RPMI), along with components such as serum, antibiotics, glutamine and 
Cell Dissociation Buffer were manufactured by Gibco and purchased from Invitrogen. MEM was 
rom Pierce 
(Rockford, IL). Slow-Fade anti-fade reagent was purchased from Molecular Probes, Inc. 
(Eugene, OR). 6-diamidino-2-phenylindole was purchased from Sigma-Aldrich and RNase was 
 
G12V
obtained from ATCC.  Corning plates for tissue culture were the purchased from ThermoFisher 
Scientific.   All chemicals were purchased from Sigma-Aldrich (St. Louis, MO).  SA-β-
Galactosidase Activity kit was purchased from Cell Signaling Technology (Danvers, MA).  
Chromatin Immunoprecipitation and TUNEL Apoptosis Detection kits were obtained from 
Upstate Cell Signaling Solutions (Temecula, CA).  All antibodies were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA), except for Ki67 which was purchased from Dako 
(Glostrup,Denmark).  Kits for cloning were purchased from Qiagen (Valencia, CA). BA83 
nitrocelluose membrane was purchased from Schleicher & Schuell (Keene, NH). ECL 
SuperSignal West Pico Chemilluminescent Substrate Kit detection kit was f
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obtained from lthcare Life Sciences 
(Piscataway, NJ).  Primers for PCR reacations were ordered from Invitrogen.  The Cavtratin 
2.2 TISSUE CULTURE 
Normal tissue culturing conditions were used to grow cells for these experiments in Corning 
 Invitrogen.  Sepharose A beads were purchased from GE Hea
peptide was purchased from Tufts University Core Facility (Medford, MA).  Nu/nu mice were 
purchased from Charles Rivers Laboratories.  
 
 
plates (Fisher Scientific) at 37°C and 5% CO2. The following cell lines were utilized for the 
listed experiments. NIH 3T3 Fibroblasts and RasG12V transformed fibroblasts were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) plus 10% donor bovine serum. Mouse 
embryonic fibroblasts (MEFs) and MCF7 cells were grown in DMEM plus 10% fetal bovine 
serum. WI-38 fetal lung fibroblasts were cultured in Minimum Essential Eagle’s Medium 
(MEM) and 10% fetal bovine serum. MDA-MB-231 cells were grown in RPMI Medium 1640 
and 10% fetal bovine serum. All of the above were supplemented with 2 mM of glutamine and 
100 units of penicillin/ 100 µg streptomycin per mL.  Human mammary epithelial cells (HMEC) 
were grown in Mammary Epithelial Basal Medium supplemented with 2 mM glutamine, bovine 
pituitary extracts (70 µg/mL), epidermal growth factor (20 ng/mL), hydrocortisone (5 µg/mL), 
insulin (10 µg/mL), gentamicin (50 µg/mL), and amphotericin (2.5 µg/mL).  
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2.3 HYDROGEN PEROXIDE TREATMENT 
Cells were treated with hydrogen peroxide for 2 hours when dish confluency was between 50-
70%. NIH 3T3 and RasG12V transformed fibroblasts, and MEFs were treated with 150 μM 
hydrogen peroxide diluted in media and HMEC, MCF7 and WI-38 cells were treated with 450 
µM hydrogen peroxide diluted in media. After treatment, cells were washed twice with PBS and 
allowed to recover for the given amount of time in their respective culturing media.  
6
2.4 CHROMATIN IMMUNOPRECIPITATION 
NIH 3T3 cells were treated with H2O2 as stated above. Cells were crosslinked by adding 1% 
formaldehyde to the cell plate containing 8 ml of growth media for 10 minutes at 37°C. The 
crosslinking was quenched with the addition of 0.8 ml of 1.4 M glycine to each plate for 5 
minutes at 4°C. Cell counts were approximately 5 x 10  cells per reaction. Cells were centrifuged 
at 600 x g for 10 minutes at 4°C, and the pellet was resuspended in 500 μL of cold Chromatin IP 
buffer (50 mM HEPES KOH pH 8, 1mM EDTA pH 8, 0.5 mM EGTA pH 8, 140 mM NaCl, 
10% glycerol, 0.5% IGEPAL, 0.25% Triton X-100 and protease inhibitors). Cells were rotated at 
4°C for 10 minutes and spun down at 600 x g at 4°C for 10 minutes. The pellet was resuspended 
in 500 μL of cold Wash Buffer (10 mM Tris-HCl pH 8, 1 mM EDTA pH 8, 0.5 mM EGTA pH 
8, 200 mM NaCl, protease inhibitors). Cells were pelleted as above and resuspended in 500 μL 
cold RIPA buffer ( 10 mM Tris-HCl pH 8, 1 mM EDTA pH 8, 0.5 mM EGTA pH 8, 140 mM 
NaCl, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS, and protease inhibitors) . The 
samples were sonicated in polypropylene tubes at an amplitude of 21%, 2 pulses on 1 pulse off, 
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for 10 seconds with 3 cycles (so the DNA was fragmented to ~250-1000 bp fragments) Samples 
were pelleted and the supernants are transferred to an eppendorf with the final volume brought to 
500 μL in RIPA buffer + protease inhibitors. This is the ChIP lysate, and it is precleared with 
Upstate Protein A Sepharose beads plus conjugated salmon sperm DNA for 30 minutes at 4°C. 
Afterward, samples are spun down and the supernant saved. 10% of the sample (50 μL) is taken 
as input. The inputs were reverse crosslinked immediately by adding 950 μL ChIP Dilution 
Buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1, and 167 
mM NaCl) with 40 ately 4 hours. ChIP lysate 
was combined with 70 μL of beads in addition to 3 ug of Sp1 antibody and rotated over night at 
4°C. Beads were centrifuged at 600 x g and washed twice for 5 minutes with rotation at 4°C with 
cold RIPA buffer, twice with cold RIPA buffer + 500 mM EGTA pH 8, and once with LiCl 
Buffer (10 mM Tris-HCl pH 8, 1 mM EDTA pH 8, 0.5 mM EGTA pH 8, 250 mM LiCl, 1% 
Triton X-100, 1% Na-deoxycholate, and protease inhibitors). Complexes were eluted twice in 
250 μL of fresh Elution Buffer (1% SDS and 0.1 M NaHCO3). Samples were reverse crosslinked 
by adding 20 μL of 5M NaCl and incubating at 65°C for approximately 4 hours. To both ChIP 
samples and inputs 10 μL of 0.5M EDTA, 20 μL of 1M Tris-HCl pH 6.5, and 2 μl of 10 mg/ml 
Proteinase K were added and incubated at 45°C for 1 hour. Inputs and sample DNA were 
y using Qiagen PCR Purification kit (Valencia, CA) according to manufacturer’s 
instructions and resuspended in 30 μL of H2O. PCR was conducted using the following 
sequences for primers: sens TCC CCG CCG, and antisense (5’ 
to 3’) GTA TAG AGG GGG GAA AGG CGC. Both ChIP samples and inputs, PCR reactions 
μ 5M NaCl and incubated at 65°C for approxim
recovered b
e (5’ to 3’) CAG GCT CTC AGC 
were prepared by adding 5 μL of sample DNA and 45 μL of a master mix containing 4 μL of 
sense and antisense primers, 27.5 μL H2O, 4 μL dNTP, 5 μL Buffer and 0.5 μL Taq enzyme 
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(Takara Bio Inc., Japan). The PCR was run at 1) 94°C for 5 minutes 2) 94°C for 30 seconds 3) 
58°C for 30 seconds 4) 72°C for 1 minute (steps 2-4 were repeated 39 times) and 5) 72°C for 7 
minutes. 40 μL of ChIP PCR were added to 8 μL TAE 6X DNA loading dye, and run out on a 
1.2% agarose gel with ethidium bromide. The gel was documented with a UV gel documentation 
device, Eagle Eye by Stratagene.  
2.5 ADENOVIRUS INFECTION 
Adenovirus carrying Cav-1 (Ad-Cav-1), GFP (Ad-GFP), and transactivator (Ad-tTA) were 
previously describ and Human 
Mammary Epithelial Cells (HMEC) were co-infected with Ad-tTA (transactivator: 100 plaque-
3 nitrocelluose membrane 
(Schleicher & Schuell, Keene, NH). Blots were blocked using 2% dried milk in TBST (10 mM 
ed (Zhang, Razani et al. 2000).  Sub-confluent MCF7 cells 
forming units/cell) and Ad-Cav-1 or Ad-GFP (500 plaque-forming units/cell) for 1 hour in 
serum-free DMEM, and washed with PBS.  Cultures were grown in complete media for the 
indicated period of time.  Cells were subjected to immunoblotting, 6-diamidino-2-phenylindole 
(DAPI) staining, or terminal deoxyribonucleo-tidyl transferase–mediated dUTP nick end labeling 
(TUNEL) analysis. 
 
2.6 IMMUNOBLOT 
Cells were collected in boiling 1X sample buffer. Samples were separated by molecular weight 
on a SDS-PAGE 12.5% polyacryamide gel and transferred to a BA8
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Tris-HCl, pH 8.0, 150 m s for monoclonal antibody 
treatment or 1% bovine serum albumin (BSA) and 2% dried milk in TBST for polyclonal 
ting Dounce homogenizer and passing the glass 
tube 10 times. The homogenate was adjusted to 40% sucrose by the addition of 2 ml of 80% 
sucrose prepared in MES buffer listed above and placed at the bottom of an ultracentrifuge tube. 
A 5-30%  centrifuged at 
39,000 rpm for 16-20 h in a SW41 rotor (Beckman Instruments). From the top of each gradient, 
M NaCl, 0.2% Tween 20) for 45 minute
antibody treatment. Blots were rinsed 3 times for 5 minutes each and incubated with primary 
antibody diluted in TBST for anywhere from 3 hours to overnight depending upon the affinity of 
the antibody. Blots were rinsed 3 times for 5 minutes and incubated with horseradish peroxidase-
conjugated goat anti-rabbit/mouse IgG diluted in the appropriate blocking buffer for 1 hour. 
Bound antibodies were detected using an ECL detection kit from Pierce: SuperSignal West Pico 
Chemilluminescent Substrate Kit (Rockford, IL).  
2.7 SUCROSE DENSITY GRADIENT CENTRIFUGATION 
Wi-38 cells were treated with 450 μM H2O2 for 2 hours and allowed to recover for 24 hours. 
Caveolae membranes were isolated by sucrose gradient centrifugation. Briefly, cells were 
collected in 2 ml of a MES buffer (0.01M MES pH 6.5, 0.15M NaCl and 1% (v/v) Triton X-
100). Cells were homogenized using a loose fit
 linear sucrose gradient was formed above the homogenate and
1-ml gradient fractions were collected to yield a total of 12 fractions. Fractions 9-11 contained 
soluble proteins and fractions 4-6 contained insoluble proteins including Cav-1. Equal amounts 
of protein from each sample were subjected to immunoblot analysis.  
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2.8 IMMUNOFLUORESCENCE 
Cells grown either on glass coverslips or culture dishes were washed 3 times in PBS/CM (a 
buffer containing 1X PBS with 0.1 mM CaCl2 and 1 mM MgCl2). Cells were fixed using 2% 
paraformaldehyde in PBS/CM for 30 minutes at room temperature. Cells were rinsed and 
permeabilized with 0.1% Triton X-100 and 0.2% BSA (bovine serum albumin) in PBS/CM 
(PBS/CM++) for 10 minutes at room temperature. This was quenched with 50 mM NH4Cl in 
PBS/CM for 10 minutes. Cells were washed once with PBS/CM++ and incubated with primary 
antibody diluted in sam dy dependent. Cells were 
washed 3X for 10 minutes each in PBS/CM++ and incubated with secondary antibody diluted in 
ith 0.1% Triton X-100 and 0.2% BSA (bovine serum albumin) in 
e solution for 2 hours. Concentration was antibo
the same buffer for 1 hour. Secondary antibodies used in these studies were: lissamine 
rhodamine B sulfonyl chloride- or Cy3-conjugated goat anti-rabbit antibody (5 μg/ml) and/or 
fluorescein isothiocyanate-conjugated goat anti-mouse antibody (5 μg/ ml). Cells were washed 
three times in PBS/CM++ and rinsed once with PBS. Slides were mounted with slow-Fade anti-
fade reagent (Molecular Probes, Inc., Eugene, OR) and observed using a Zeiss Confocal 
microscope or Olympus Confocal microscope.  
2.9 4’,6-DIAMIDINO-2-PHENYLINDOLE STAINING 
Cells were grown on glass coverslips or just the culturing dish. Cells were washed 3 times in 
PBS/CM (a buffer containing 1X PBS with 0.1 mM CaCl2 and 1 mM MgCl2). The cells were 
fixed using 2% paraformaldehyde in PBS/CM for 30 minutes at room temperature. Cells were 
rinsed and permeabilized w
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PBS/CM (PBS/CM++) with 10 μg/ml RNase for 10 minutes at room temperature. This was 
quenched with 50 mM NH4Cl in PBS/CM for 10 minutes, and cells were washed once with 
in 
 with 
gene, 
er 
M octyl 
le 
mples 
 for 
 μL; 
 1 
e 
sed: 
ted to protein A Sepharose beads. Samples were 
treated the same as above.  
PBS/CM++. Cells were incubated with 1 μg/ml 4’, 6-diamidino-2-phenylindole (DAPI) 
PBS/CM++ for 20 minutes. Cells were washed three times in PBS/CM++ and rinsed once
PBS. Slides were mounted with slow-Fade anti-fade reagent (Molecular Probes, Inc., Eu
OR) and observed using a Zeiss Confocal microscope or Olympus Confocal microscope.  
2.10 CO-IMMUNOPRECIPITATION 
All steps were carried out at 4°C. Cells were washed twice in PBS and lysed in an IP buff
containing 10 mM Tris, pH 8.0, 0.15 M NaCl, 5 mM EDTA, 1% Triton X-100, 60 m
glucoside and protease inhibitors. Samples were put on rotation for 45 minutes at 4°C. Solub
supernant was precleared with using protein A-Sepharose (20 μL; slurry, 1:1) at 4°C. Sa
were centrifuged at 10,000 rpm for 10 minutes and supernant was taken and normalized
protein concentration. One tenth of the volume was taken as an aliquot for total input. The 
supernant was incubated over night with the particular antibody and protein A-Sepharose (30
slurry, 1:1). Beads were washed in lysis buffer 4 times on rotation for 10 minutes at 4°C. The 
final wash was done with 2.5 mM of Tris-HCl pH 7.5. Beads were spun down at max speed for
minute and sample buffer was added. Results were resolved by immunoblot analysis on th
samples and the inputs. For immunoprecipitations using MDM2, the following buffer was u
50 mM Tris, pH 8.0, 0.15 M NaCl, 5 mM EDTA, 1% NP-40. Samples were not precleared and 
were incubated with anti-MDM2 IgGs conjuga
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2.11 
to manufacturer’s 
g 1 µL oligo 
on 
 
CR reactions. The PCR program used was the 
following: 1) 94°C for 5 seconds 2) 94°C for 45 seconds 3) 58°C for 45 seconds 4) 72°C for 2 
minutes 5) steps 2-4 are repeated 29 times 6) 72°C for 7 minutes and cooled to 4°C.  PCR 
 
Mdm2 oligos were cut using the EcoR1 and BGL2 restriction enzymes and gel purified using the 
MDM2 AND CAVEOLIN BINDING DOMAIN MUTANT MDM2 CONSTRUCTS 
RNA was isolated from 30 mg of mouse lung using the RNeasy Mini Kit from Qiagen. cDNA 
was generated using Advantage RT-for-PCR Kit by Clontech according 
instructions. Briefly, 1 μg of RNA was used and RT-PCR was conducted usin
(dT)18.   Using the cDNA as template, and using the following Mdm2 primers in a PCR reacti
MDM2 was amplified: 5’ ccggccgaattcatgtgcaataccaacatgtct and 
3’ccggccagatctttaattcagatcttcctcgctgatcagtttctgttcgcgccgttgaagtaagttagcacaat. The 3’ primer 
includes a myc tag. The following components and the quantity of each were used in the PCR 
reaction: 5 µL MgSO4, 5 µL DNA template, 5 µL Buffer 10X, 4 µL dNTPs, 5 µL 3’oligo primer,
5 µL 5’ oligo primer, 24.5 µL H2O, and 0.5 µL Taq enzyme.  Invitrogen’s Platinum Pfx DNA 
polymerase was used in all subsequent P
products were purified using the PCR Purification Kit by Qiagen. The pCAGGS vector and
QIAquick Extraction from Qiagen. The gene products were ligated into the pCAGGS vector 
overnight at 37°C, and transformed into DH5α E. coli. Briefly, the ligation reaction was added to 
the bacteria on ice for 30 minutes. The samples were heat shocked in a 37°C water bath for 30 
seconds and placed back on ice for 2 minutes. 1 ml of LB was added to the samples along with 
ampicillin and they were incubated at 37°C for 1 hour. The culture was plated on ampicillin 
plates. Colonies were selected and the constructs were isolated using Qiagen Mini and Maxi Prep 
Kits according to manufacturer’s instructions.  
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The Myc-tagged Mdm2construct was used as a template to make a mutated Mdm2 (Φ→A 
Mdm2-Myc). The mutant Mdm2 construct was made by point mutations.  Mutant primers 
converted nucleotides corresponding to amino acids tyrosine 48, phenylalanine 55, tyrosine 56 
and 60 
2.12 GST-FUSION CAVEOLIN SCAFFOLDING DOMAIN PULL-DOWN 
GST-Cav-1 fusion proteins were synthesized with the full length, amino acids 42-101 and 82-
to alanines. The following primers were used: Mdm2 MUTANT 
3’cataatagcctggccaatagcagctataatctctttcatagtggcagtgtc and Mdm2 MUTANT 
5’gacactgccactatgaagagattatagctgctattggccaggctattatg.  Using the Myc- Mdm2 construct as a 
template, the following primer combinations were used in 2 reactions: 1) Myc- Mdm2 5’+ 
Mdm2MUTANT 3’and 2) Mdm2 MUTANT 5’ and Myc- Mdm2 3’.  Reactions 1 and 2 were 
combined to use as template for the final reaction with primers Myc- Mdm2 5’ and Myc- Mdm2 
3’.  PCR product from this reaction was cloned into pCMV-HA using the same method as listed 
above for the Myc- Mdm2 construct.  The University of Pittsburgh Genomics and Proteomics 
Core Facility sequenced all constructs. 
101 of the caveolin-1 protein. The constructs were transformed into Escherichia coli (BL21 
strain; Novagen Inc.). When cultures reached OD600=0.3-0.6, cultures were induced with 0.5 mM 
isopropyl-β-D-thiogalactopyranoside (Sigma Aldrich). The fusion proteins were solublized by 
using 100 μg/ml lysozyme, 5 mM DTT and 1.5% N-lauryl sarkosyl in STE buffer (150 mM 
NaCl, 7.52 mM Tris pH 8.0 and 3 mM EDTA pH 8.0) and a polytron was utilized to lyse the 
bacteria. The constructs were affinity purified by binding to glutathione-agarose beads washed in 
STE with 2.0% Triton X100 overnight at 4°C. Beads were washed in STET (150 mM NaCl, 7.52 
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mM Tris pH 8.0 and 3 mM EDTA pH 8.0, 1% Triton X-100 plus protease inhibitors) 3 times. To 
determine the concentration of GST-Cav-1 per 100 μL of packed bead volume, SDS-PAGE 
followed by coomassie staining was conducted.  
The GST pulldown was conducted on 3T3 NIH fibroblasts cultured in 10 cm dishes. 
A 
Mdm2) DNA by the calcium phosphate m ter cells were lysed in IP buffer( 10 
mM Tris-HCl pH 8.0, 150 mM NaCl2, 5 mM EDTA, 1% Triton X100, 60 mM n-octyl glucoside, 
protease inhibitors). Cells were put on rotation for 45 minutes at 4°C, and the soluble fractions 
were collected. Lysates were precleared with glutathione-agarose beads for 1 hour. Samples were 
normalized based on protein concentration. Samples were incubated overnight with beads fused 
to GST alone, GST-full length Cav-1, GST-1-101 amino acids, or GST-81-101 amino acids at 
4°C. Beads were washed 3 times in IP buffer, resuspended in sample buffer and subjected to 
SDS-PAGE. 
Cells were transfected with 30 μg of Wildtype Mdm2 (WT- Mdm2) or mutant Mdm2 (Φ→
ethod. 48 hours la
2.13 CELL PERMEABLE CAVTRATIN PEPTIDE 
Cavtratin is a cell-permeable peptide consisting of the caveolin scaffolding domain amino acids 
82-101 (DGIWKASFTTFTVTKYWFYR) fused to the C-terminus of the internalization 
sequence of the Drosophila transcription factor antennapedia (AP) (RQIKIWFQNRRMKWKK), 
by Fmoc chemistry, purified and analyzed by reversed-phase high pressure liquid 
chromatography and mass spectrometry by the Tufts University Core Facility. Detection of the 
peptide was possible because of the biotin tag followed by an aminohexanoic acid spacer added 
to the amino terminus of the AP fusion peptide. The peptide was solublized in DMSO. WI-38 
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cells w
NIH 3T3 fibroblasts were cultured in 6-well plates with 300,000 cells/well.  Cells were 
transfected using calcium phosphate with the following DNA construct amounts: 3 μg of 
luciferase reporter fused to the p53 responsive element called p53 transactivator (pTA-p53) and 
pSV- β-galactosidase.  After another 24 hours, cells were rinsed twice with 1X PBS and 
ellular 
media for 24 hours.  A luciferase assay was conducted.  Cells were washed twice in 1X PBS and 
 using a luminometer injecting 100 µl of luciferin 
substrate (Molecular Probes, Oregon) solution per tube (1mM luciferin substrate, 50 mM DTT).  
ere treated with 4μM or 10 μM for 24 hours and subjected to immunoblot, 
immunoprecipitation, luciferase assay and SA-β-galactosidase staining.  
2.14 P53 RESPONSIVE ELEMENT LUCIFERASE ASSAY WITH CAVTRATIN 
TREATMENT 
incubated with cavtratin (10μM) or the control peptide Antennapedia (AP) (10μM) in c
lysed at 4°C in 500 μL of Extraction Buffer (1% w/v Trition-X-100, 1 mM DTT, GME Buffer: 
25 mM glycylglycine, 15 mM MgSO4, 4 mM EGTA, dissolved in H2O) and placed on a rocker 
at 4°C for 30 minutes.  During this incubation, 300 μL of ATP Mix (GME Buffer, 100 mM K 
Phos, 1 M DTT, 200 mM ATP – kept at room temperature) is placed into cuvettes for luciferase 
assay and 600 μL of Z buffer (100 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, pH 7.0) with 50 
mM β-mercaptoethanol added before aliquoting into eppendorf tubes for the β-galactosidase 
assay.  Each experimental sample was run in duplicate for β-galactosidase and luciferase assay. 
100 μL of sample is added into each cuvette for the luciferase assay and 100 μL of sample into 
each eppendorf for the β-galactosidase assay.  All are vortexed briefly to mix.  Once this was 
completed, the luminometer cuvettes were read
 47 
For the β-galactosidase assay, 20 μL of CPRG (chlorophenol red-β-galactopyranoside, 
Boehringer Mannheim) was added into the eppendorf tubes.  The reaction proceeded until there 
med. 
 
 
ge with an 
18-gauge needle with 3 ml of trypsin and placed in a 10 cm culturing dish. The embryo 
fragments were incubated at 37°C for 5 minutes. 17 ml of MEF media (Dulbecco Modified 
Eagle’s Medium, 10% fetal bovine serum, glutamine and penicillin/streptomycin) were added to 
the dish and the sample was pipetted up and down to break up tissue fragments. The dish was 
incubated overnight. The next day large tissue fragments were removed, and the remaining 
annealed fibroblasts were cultured as normal.  
was a color difference between the blank and the samples (30 minutes- 2 or more hours).  
Reaction was stopped with the addition of 200 μL of 1 M Na2CO3.  Absorbance was measured at 
λ= 574 nm.  The p53 luciferase reporter activity was controlled for transfection efficiency and 
potential toxicity with the use of β-galactosidase activity. For each condition, at least three 
independent experiments were perfor
2.15 ISOLATION OF PRIMARY MOUSE EMBRYONIC FIBROBLASTS 
At 13.5 days of gestation a pregnant mouse was sacrificed by isoflorane exposure and cervical 
dislocation. The uterus was removed and cleaned in sterile PBS. Embryos were isolated and 
removed from the embryonic sacs. The liver was discarded and the head used to genotype the 
embryos. The remaining embryo was passaged through a sterile 6 cc luer lock syrin
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2.16 PROTEOSOMAL INHIBITION OF CAV-1 NULL MEFS 
Cav-1 null mouse embryonic fibroblasts were treated with 150 μM hydrogen peroxide diluted in 
media for 2 hours, washed twice in 1X PBS and allowed to recover in normal media for 18 
hours.  Cells were given 5 μM of proteasomal inhibitor MG132 dissolved in DMSO or the 
equivalent amount of DMSO for 6 hours.  Cells were lysed and immunoblot analysis was done to 
determine p53 or p21 protein levels. 
2.17 SENESCENCE-ASSOCIATED ß-GALACTOSIDASE STAINING 
Cells were cultured under normal conditions and treated as stated. Cells were washed twice with 
PBS and fixed with 2% formaldehyde/0.2% glutaraldehyde at room temperature for 15 minutes. 
Cells were again washed twice with PBS and stained with Senescence Associated-β-
Galactosidase stain (7.36 mM citric acid/sodium phosphate dibasic pH 6.0, 150 mM NaCl, 2 mM 
MgCl2, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide and 1 mg/ml X-gal. 
2.18 CO-CULTURING OF MEFS WITH RASG12V AND MDA-MB-231 EPITHELIAL 
CELLS 
Three different populations of either wildtype or knockout MEFs were mixed and plated so on 
the day of the hydrogen peroxide treatment MEFs were approximately 50% confluent. For the 
overnight at 37°C. Plates were covered with 70% glycerol in PBS and stored at 4°C.  
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treatment, MEFs were exposed to 150 µM of hydrogen peroxide in the culturing media for 2 
hours. Cells were washed with 1X PBS twice and complete media was replaced. Cells recovered 
for 4 days and were starved for 3 days in serum-free media for co-culturing.  RasG12V and MDA-
MB-231 cells were starved in their respective media for 3 days in concurrence with the MEF 
cells.  Additionally, the MDA-MB-231 cells were supplemented with 5µg/ml of insulin when 
starved in serum free media.  Cells were co-cultured by trypsinizing the RasG12V or MDA-MB-
231 cel op of the 50% 
confluent starved 10 cm plate of MEFs or 37,500 MDA-MB-231 on top of the starved 6 cm plate 
of MEFs.  Co-cultures were grown for 7 days, and stained with DAPI and Ki67 (Ras  co-
cultures) or DAPI and crystal violet (MDA-MB-231 co-cultures).  For Ras  co-cultures, 
results were quantified by counting the number of nuclei or Ki67 positive cells in 30 random 
fields per sample.  For MDA-MB-231, results were quantified by counting the number of 
colonies in the DAPI stained dishes with greater than 20 cells, and the crystal violet 
quantification is found under section 2.21.  
2.19 CONTRIBUTION OF EXTRACELLULAR MATRIX AND SECRETORY 
FACTORS IN CO-CULTURE PROLIFERATION 
Wildtype and Cav-1 knockout MEFs were treated with oxidative stress and starved the same way 
Before co-culturing, conditioned media was collected and saved from the MEFs.  The MEF 
plates were washed twice with PBS and cells were removed by incubating in Cell Dissociation 
Buffer in PBS (Gibco) for 1-2 hours or until >90% of MEFs were removed from the dish.  The 
ls, neutralizing in complete media, and layering: 37,500 RasG12V cells on t
G12V
G12V
as listed above under co-cultures in section 2.17.  RasG12V were also starved as stated above.  
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dishes al debris, cells, or dissociation 
uffer.  Conditioned media was replaced onto the respective dishes along with   37,500 NIH 3T3 
asG12V transform ere q as cells under Co-
ultures section 2
2. A URES 
DA-MB-231 ce to crystal violet staining by incubating the cells with 0.1 
ram per ml crystal violet in 70% ethanol for 2 minutes followed by extensive washes with PBS.  
2
2.21 TUMORGENESIS ASSAY 
Wildtype and Cav-1 knockout mouse embryonic fibroblasts were treated with 150 µM of 
hydrogen peroxide in the culturing media for 2 hours.  Cells were rinsed twice with 1X PBS and 
allowed to recover for 7 days.   The chart l combinations, which were 
subcutaneously injected into the dorsal flap of nude (nu/nu) mice (5-6 weeks old from Charles 
were washed with PBS three times to remove any residu
b
R ed fibroblasts.  Results w uantified as listed for R
c .19. 
20 CRYSTAL VIOLET ST INING OF CO-CULT
M lls were subjected 
g
Quantification of crystal violet staining was performed as followed: the image was preprocessed 
by cropping the central area of each plate, converting to the HSV color space, and finding 
connected regions of pixels with saturation greater than 0.2 on a [0, 1] scale. To reduce noise, 
only colonies with an area of  > 32 pixels were counted ( ≥0.3mm ).  
below shows the cel
Rivers Laboratories):  
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Table 1.  Cell number and combinations injected into nude mice. 
 
 
 
 
 
 
 
 
 
All cells were resuspended into a 100 μL volume of PBS.  Four weeks after the injection, tumors 
were excised and the x and y axes measured to determine tumor volume (size) according to the 
following formula: volume = 0.5 x width2 x length. When only one population of cells was 
injected, two mice were injected in duplicate for a total of 4 tumor masses for each population of 
cells.  When two populations were injected in combination, three mice were injected in duplicate 
totaling 6 measurable tumor masses for each combination.  This animal protocol was reviewed 
and approved by the Institutional Animal Care and Use Committee at the University of 
Pittsburgh. 
2.22 STATISTICAL ANALYSIS 
Statistical analyses of data were conducted using Microsoft Excel software.  The averages were 
determined using the AVERAGE function.  Standard error of the mean was determined by 
CELL COMBINATION NUMBER OF CELLS 
MDA-MB-231 ONLY 325,000 
RAS ONLY 325,000 
WT OR KO MEFS ONLY 1,000,000 
MDA-MB-231 + KO MEFS 325,000 + 1,000,000 
MDA-MB-231 + WT MEFS 325,000 + 1,000,000 
RAS + KO MEFS 325,000 + 1,000,000 
RAS +WT MEFS 325,000 + 1,000,000 
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dividing the sample estimate of the standard deviation (computed with the STDEV function) by 
the square root of the number of values in the sample.  The p-values were calculated using the 
Student's T-test. 
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3.0 OXIDATIVE STRESS INDUCES PREMATURE SENESCENCE BY 
STIMULATING CAVEOLIN-1 GENE TRANSCRIPTION THROUGH P38 MITOGEN-
PROMOTER ELEMENTS 
cell
rowth (Engelman, Wycoff et al. 1997). 
 
ACTIVATED PROTEIN KINASE/ SP1-MEDIATED ACTIVATION OF TWO GC-RICH 
3.1 INTRODUCTION 
Cav-1 has been indicated to be a tumor suppressor.  The protein has been shown to inhibit 
signaling molecules associated with cell proliferation, and it is down-regulated in many cancers.  
For example, the Cav-1 gene is hypermethylated in certain colon cancers (Mori, Cai et al. 2006). 
It is also downregulated in invasive ductal carcinoma of the breast (Park, Kim et al. 2005) and 
inactivated by downregulation or mutation in oral cancer (Han, Park et al. 2004).  The caveolin-1 
gene is localized at chromosome 7q31.1, a region deleted in many human cancers (Razani, et al 
2002 and van Deurs, et al. 2003). Cav-1 is down-regulated in many human breast cancer cell 
lines and re-introduction of the protein into these s result in growth inhibition and reduced 
colony formation in soft agar (Lee, Reimer et al. 1998).  Down-regulation of Cav-1 in NIH 3T3 
fibroblasts leads to cellular transformation (Koleske, Baltimore et al. 1995).  In the 3T3 
fibroblasts transformed by v-Abl or H-RasG12V the induction of Cav-1 abrogates anchorage-
independent g
 54 
While down regulation of Cav-1 is linked to cancer, there is also evidence connecting  
high levels of caveolin-1 with cellular  senescence.  Cav-1 over-expression can cause the growth 
arrest of mouse embryonic fibroblasts in G0/G1, reduce proliferation, and induce p53/p21 
dependent SIPS (Galbiati, Volonte et al. 2001; Volonte, Zhang et al. 2002). Over-expression of 
Cav-1 is sufficient to induce premature senescence.  Likewise, endogenous Cav-1 expression is 
up regulated in senescent cells.  Oxidative SIPS is mediated by an up-regulation of Cav-1 
(Volonte, et al. 2002). Cav-1 may play a role in aging because the protein’s expression increases 
in aged tissues (Cho, et al.  2003).  Additionally, the senescent phenotype is reversed by a 
reduction in Cav-1 expression by siRNA (Cho, Ryu et al. 2003). 
Subcytotoxic levels of hydrogen peroxide treatment to cells generate SIPS with the 
characteristic phenotype of an e cessation of DNA replication, and 
senescence associated-ß-galactosidase activity (Chen, Bartholomew et al. 1998; Frippiat, Chen et 
al. 2000; Frippiat, Dewelle et al. 2002).  Work on the signaling pathway leading to SIPS shows 
p38  is phosphorylated in IMR-90 hTERT cells after hydrogen peroxide treatment (Zdanov, 
Debacq-Chainiaux et al. 2006), and oncogenic induced SIPS occurs through activation of 
p38  (Deng, Liao et al. 2004).  Further research shows the initial cellular insult does not 
activate p38MAPK, but activation of the kinase is through an unidentified cellular condition caused 
by the insult (Iwasa, Han et al. 2003).  One of p38 ’s downstream targets is the transcription 
factor Sp1 (D'Addario, Arora et al. 2006).  Hydrogen peroxide increases phosphorylation of Sp1 
(Chu and Ferro 2006).  Additionally, multiple phosphorylations of Sp1 induces the transcription 
factor’s binding to GC rich regions in DNA (Kadonaga, Carner et al. 1987; Jackson, MacDonald 
et al. 1990). 
nlarged morphology, 
MAPK
MAPK
MAPK
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Subcytotoxic hydrogen peroxide treatment amplifies expression of Cav-1, which is 
followed by an escalation of p53 activity and SIPS (Volonte, Zhang et al. 2002).  The oxidative 
stress signal transduction pathway leading to Cav-1 upregulation and SIPS is not well defined.  
Here w
3.2.1 Oxidative stress activates Sp1 which binds to GC-rich regions in the Cav-1 
promoter 
Increased Cav-1 protein expression from oxidative stress is necessary for SIPS in fibroblasts 
(Volonte, Zhang et al. 2002).  The signaling events leading to Cav-1 upregulation are undefined.  
To identify oxidative stress response elements in Cav-1’s gene promoter, deletion mutants of the 
promoter were fused to the luciferase gene.  These constructs were transfected into NIH 3T3 
fibroblasts and 24 hours later were treated with 150 µM H2O2 for 2 hours, rinsed and allowed to 
recover for 2 days in normal media.  A luciferase activity assay identified 2 oxidative responsive 
elements between nucleotides -372 to -222 and -150 to -91 in the Cav-1 promoter.  Analysis of 
these regions revealed GC-rich boxes.  To determine whether these GC boxes were responsive to 
oxidative stress, the nucleotide sequences were fused to a luciferase gene.  The constructs were 
e hypothesize p38MAPK may be a factor leading to Cav-1 up-regulation through Sp1.  
Additionally we explore SIPS in breast cancer epithelial cells.  If a cancer cell retains wildtype 
p53 activity, it should be possible for these cells to undergo Cav-1 dependent senescence.  We 
hypothesize MCF7 cells, a wildtype p53 but null Cav-1 breast cancer cell line, will not undergo 
senescence from oxidative stress. 
3.2 RESULTS 
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transfected into NIH 3T3 fibroblasts and were treated with hydrogen peroxide as listed above.  A 
luciferase activity assay shows nucleotides -244/-22 and -124/-101 in the Cav-1 prom
responded to hydrogen peroxide (data not shown) (Dasari, Bartholomew et al. 2006). 
Electromobility shift assays (EMSAs) were utilized to determine whether prot
bind to the oxidative stress response elements found.  Nuclear extracts from cells treated ± 
hydrogen peroxide were incubated with nucleotide oligos of the identified GC-rich oxidative 
stress response elements.  Data from EMSAs reveal nucleotide sequences -244/-222 and -124/-
 the Cav-1 promoter formed nucleoprotein complexes upon hydrogen peroxide 
oter 
eins would 
101 from
treatment.  Lysates from cells treated with hydroge
unlabelled Sp1 consensus sequences. There was decreased formation of nucleoprotein complexes 
ChIP.  Results show increased binding of Sp1 to the Cav-1 promoter after oxidative stress 
n peroxide were incubated in the presence of 
(data not shown) (Dasari, Bartholomew et al. 2006). A chromatin immunoprecipitation (ChIP) 
was done with the Sp1 antibody to determine whether Sp1 directly binds to the GC-boxes in the 
Cav-1 gene promoter after oxidative stress.  NIH 3T3 cells were treated with or without 
hydrogen peroxide as described for the EMSA assay.  Input was taken of the samples prior to 
compared to non-treated controls (Figure 4). 
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 Figure 4.  Sp1 binds directly to the Cav-1 gene promoter upon oxidative stress. Chromatin 
immunoprecipitation (ChIP) assay was done on chromatin derived from untreated or hydrogen peroxide–treated 
(150 µM for 2 hours) NIH 3T3 cells 48 hours after oxidative stress.  Briefly, DNA was crosslinked with 1% 
formaldehyde and samples were normalized based on cell number.  Sonication was used to produce DNA fragments 
approximately 250-1000 bp in length.  ChIP lysate was precleared with Protein A Sepharose beads conjugated to 
put.  ChIP lysate was 
incubated with the beads and 3 µg Sp1 antibody overnight.  A control was done using a random antibody that did 
amplifying the region of the caveolin-1 promoter containing the two GC-rich boxes.  Amplification of input DNA 
2 2
d and allowed to recover for 48 hours.  Immunoblot analysis using 
anti-Sp1 shows the protein’s expression increases from oxidative stress. 
salmon sperm DNA for 30 minutes at 4°C.  Ten percent of the sample was taken for In
not bind to the promoter (data not shown).   Samples were reverse crosslinked and PCR was done using primers 
from both untreated and hydrogen peroxide (H O )-treated cells was done before immunoprecipitation. A vector 
containing the entire caveolin-1 promoter sequence was used as a positive control for PCR.  Results show Sp1 
binding to the Cav-1 promoter after oxidative stress. 
 
The Sp1 transcription factor is known to bind to GC-rich regions and mediate oxidative 
stress-induced gene transcription (Yang, Wilson-Van Patten et al. 2000; Ryu, Lee et al. 2003; 
Schafer, Cramer et al. 2003).  In Figure 5, NIH 3T3 cells were treated with 150 µM hydrogen 
peroxide for 2 hours, rinse
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Figure 5.  Sp1 expression increases in response to oxidative stress in fibroblasts. NIH 3T3 cells were treated 
with or without 150 µM hydrogen peroxide (H2O2) for 2 hours. After 48 hours, cells were collected and the 
Immunoblotting with anti-ß-actin IgGs was done to show equal loading. 
3.2.2 Contribution of p38MAPK to stress induced premature senescence 
We showed that p38MAPK is activated by phosphorylation 48 hours after oxidative stress from 
hydrogen peroxide.  NIH 3T3 fibroblasts were transfected with the GC-rich regions of the 
caveolin-1 promoter fused to a luciferase gene and treated with hydrogen peroxide in the 
presence or absence of the p38MAPK inhibitor SB203580.  Results from a luciferase reporter assay 
show dim
expression of endogenous Sp1 was evaluated by immunoblotting analysis with an antibody probe specific for Sp1. 
inished activity at the oxidative stress response sites in the Cav-1 promoter when 
p38MAPK is inhibited.  Likewise, Cav-1 and p21WAF/CIP1 are not upregulated after oxidative stress 
when p38MAPK is inhibited by SB203580. Inhibition of p38MAPK also prevented SIPS as observed 
by senescence associated-ß-galactosidase staining activity (data not shown) (Dasari, 
Bartholomew et al. 2006). 
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3.2.3 Breast cancer cells with a Cav-1 null background undergo apoptosis when treated 
with oxidative stress 
MCF7 cells are human breast cancer derived epithelial cells with wildtype p53 expression
(Olivier, Bautista et al. 1998). Cav-1 is downregulated in MCF7 cells compared to normal 
human mammary epithelial cells (HMEC) due to hypermethylation of CpG islands in the 
promoter sequence (Engelman, Zhang et al. 1999). Because of this background, the assumption 
was made that MCF7 cells should not be able to undergo SIPS when treated with hydrogen 
peroxide.  It is hypothesized Cav-1 will be needed to rescue the SIPS phenotype after oxidative 
stress.  Cav-1 expressing HMECs were utilized as a control and do not have the 
hypermethylation in the gene’s promoter (Engelman, Zhang et al. 1999).  HMEC and MCF7 
cells were equally plated and treated with 450 μM hydrogen peroxide for 2 hours, rinsed twice 
with PBS and allowed to recover for 24 hours.  Immunoblot analysis of normalized cellular 
lysate shows the MCF7 cells do not upregulate Cav-1, whereas the HMEC cells actually increase 
Cav-1 expression after oxidative stress (Figure 6A).  Observation of cell morphology and cell 
number showed MCF7 cells were dying (Figure 6B).  Twenty-four hours after treatment, MCF7 
cells decreased in number by 60% based on total cell number from 10 random fields (Figure 6C).  
In contrast, HMEC cells did not decline in cell number and their morphology had no drastic 
change.  
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Figure 6.  MCF7 cells lacking Cav-1 expression do not survive oxidative stress.  HMEC and MCF7 cells were 
treated with 450 µM of hydrogen peroxide for 2 hours, rinsed and allowed to recover in normal media for 24 hours. 
The cells were lysed, normalized based on protein concentration and subjected to SDS-PAGE.  Immunoblot analysis 
using anti-Cav-1 shows expression and oxidative upregulation in the HMEC but not the MCF7 cells.  Anti-β-actin 
shows equal loading (A).  Representative field of HMEC and MCF7 cells treated as listed in A (B).  Cells were 
treated as listed in (A) and 24 hours later, ten random fields were counted for cell number and expressed as a total 
cell number percentage (C).  There was a 60% decrease in the number of MCF7 cells after oxidative stress. 
Columns, mean; SE.  *, P<0.005 
 
MCF7 cells treated with oxidative stress show diminished cell number (Figure 6). DAPI 
staining and Terminal Transferase dUTP Nick End Labeling (TUNEL) assays were conducted to 
determine whether these cells were going through programmed cell death. Results from DAPI 
staining show HMEC’s nuclei do not condense, regardless of whether cells are treated with ± 
hydrogen peroxide.  In contrast, MCF7 cells show marked condensation of cellular nuclei, a
marker of apoptosis (Figure 7A).  To further explore the possibility of apoptosis in these cells, a 
TUNEL assay was conducted. Results show treated and untreated HMEC and –H2O2 MCF7 cells 
did not exhibit TUNEL positive cells, as expected from cell number assays and DAPI staining. 
However, MCF7 cells treated with oxidative stress had an approximately 55-fold increase in 
TUNEL positive cells in comparison (Figure 7B). 
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Figure 7.  Oxidative stress induces apoptosis in epithelial breast cancer cells.  Human mammary epithelial cells 
and MCF-7 cells were treated with or without hydrogen peroxide (450 µmol/L) for 2 hours and allowed to recover 
for 24 hours.  Nuclear morphology was examined by DAPI staining. Representative field shows HMEC nuclei do 
not change, whereas there is nuclei condensation in the MCF7 cells (A). Apoptotic cells were detected by TUNEL 
analysis. Cells were treated as listed in (A).  TUNEL was conducted according to manufacturer’s instructions (see 
Materials and Methods).  The total number of TUNEL-positive cells was counted per 10 random fields (B). 
 
Since the HMEC increase Cav-1 expression, we hypothesized these cells would undergo 
oxidatively stressed induced SIPS.  SA-β-galactosidase staining of HMEC cells shows after 
hydrogen peroxide treatment, HMEC cells exhibit an 80% increase in cells stained positive for 
SA-β-galactosidase as compared to untreated cells.  MCF7 cells ± hydrogen peroxide do not have 
any significant change in the amount of cells positive for SA-β-galactosidase (Figure 8). 
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3.2.4 SIPS phenotype is restored by expression of Cav-1 in MCF7 cells 
MCF7 cells contain a wildtype p53 gene.  Thus, its conceivable that restoration of SIPS by p53 
up-regulation in these breast cancer cells would be restored by Cav-1 re-expression. To test this 
hypothesis an adenovirus carrying the gene for Cav-1 (Ad-Cav-1) was utilized to infect MCF7 
Figure 8.  Oxidative stress induces SIPS in HMEC but not MCF7 cells.  Cell lines were treated as in Figure 6.  
Untreated cells were used as a control. Cells were subjected to senescence-associated ß-galactosidase activity assay 
and observed under a BX50WI Olympus Optical light microscope at a magnification of x10.  Values represent 
means ± SEM. *P<0.001. 
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cells along with an adenovirus containing GFP (Ad-GFP) for a control.  Cells were infected as 
described in the Materials and Methods section.  An immunoblot shows 48 hours after infection, 
Ad-Cav-1 restored Cav-1 expression in MCF7 cells (Figure 9A).  To determine whether this 
would allow MCF7 cells to undergo SIPS upon oxidative stress, cells were infected with Ad-
GFP or Ad-Cav-1 and 24 hours later cells were treated with hydrogen peroxide and allowed to 
recover for 24 hours.  Results show that the average number of cells in 10 random fields is over 
2-fold greater in Ad-Cav-1 than Ad-GFP (Figure 9B).  Likewise, DAPI staining of infected cells 
shows a greater number of condensed apoptotic nuclei in Ad-GFP than in Ad-Cav-1 (Figure 9C). 
This trend of Cav-1 re-expression protecting from apoptosis was also present when TUNEL 
assay was conducted.  TUNEL positive cells decreased by 70% with the re-expression of Cav-1 
as compared to Ad-GFP cells (Figure 9D). Since MCF7 cells were not undergoing apoptosis 
after Cav-1 re-expression, we wanted to determine whether Cav-1 could rescue the SIPS 
phenotype in these cells.  Infected MCF7 cells were treated with oxidative stress and recovered 
for 7 days (during which time they underwent additional infections with virus).  An assay for 
senescence associated-β-galactosidase staining shows that Ad-Cav-1 restores senescence in 
MCF7 cells.  Ad-GFP MCF7 cells underwent apoptosis (Figure 9E). 
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 Figure 9.  Re-expression of Cav-1 decreases apoptosis in MCF7 cells and induces SIPS.   MCF-7 cells were 
pression 
shows th
Nuclear morphology was examined by DAPI staining and a representative fields is shown in (C). Apoptotic cells 
were detected by TUNEL analysis.  The total number of TUNEL-positive cells is expressed as a relative percentage. 
owed to
 
infected with green fluorescent protein (GFP) or caveolin-1 using adenovirus. 24 hours later, cells were treated with 
450 µM hydrogen peroxide for 2 hours and allowed to recover for 24 hours.  An immunoblot for Cav-1 ex
at infection increases the protein’s expression (A).  Counting of 10 random fields showed that Cav-1 
expression increased total cell number after oxidative stress (B). Values represent means ± SEM. *P<0.005.  
Columns, mean; bars, SE. *, P < 0.005 (D). MCF7 cells were infected with GFP or Cav-1 as in (A) and all  
recover for 7 days.  Cells were subjected to senescence-associated-β-galactosidase activity assay and observed under 
a BX50WI Olympus Optical light microscope at a magnification of x10. Representative field (E).  
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3.3 DISCUSSION 
Aging is a multifaceted process associated with many physiological changes.  A common 
hypothesis is the accumulation of somatic mutations, damage by ROS and the contribution of 
antagonistic pleiotropic genes add to aging.  Current aging research indicates that cellular 
senescence plays a role in the aging process (Campisi 1996; Smith and Pereira-Smith 1996; 
Camp late with age (Dimri, 
Lee et al. 1995; Mishim
mpisi 2005) 
there is odd xplore the 
benefits of aging by exam cer. 
The m  and is the target 
  Cav-1 expression is 
known to increase in ag it is upregulated when 
WAF/CIP1 
dependent SI erous cancers 
(Williams ; Chen, Lin et 
ents in the Cav-1 
prom
ich was necessary for th  
We propose that oxidative stress induces cellular changes, which phosphorylated p38MAPK 
isi 1997).   This is supported by data showing senescent cells accumu
a, Handa et al. 1999; Herbig, Ferreira et al. 2006; Jeyapalan, Ferreira et 
al. 2007).  Interestingly, while senescence is a tumor suppressor mechanism (Ca
ly an increased cancer risk with age.  Therefore, it is imperative to e
ining cellular senescence and how it can protect against can
embrane scaffolding protein, Cav-1, is linked to aging and cancer,
of our current studies to delineate the mechanisms of aging and cancer.
ing tissues (Kawabe, Grant et al. 2001).  Likewise, 
cells are subjected to oxidative insult.  Interestingly, Cav-1 is necessary for p53 and p21
PS (Volonte, Zhang et al. 2002).  Cav-1 is also downregulated in num
 and Lisanti 2005), and in particular, breast cancer (Xie, Zeng et al. 2003
al. 2004; Zhang, Shen et al. 2005).  
While oxidative stress upregulates Cav-1, the signal transduction pathway leading to the 
protein’s upregulation is not known.  We discovered oxidative stress elem
oter respond to hydrogen peroxide treatment.  These regions contain GC-rich boxes, which 
we hypothesized would be activated by Sp1 binding.  Preceding this we found that oxidative 
stress caused p38MAPK activation, wh e upregulation of the Cav-1 gene. 
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resulting in its activation and subsequent activation of its downstream target Sp1.  Sp1 binds to 
the GC-boxes in the Cav-1 promoter, upregulating the protein’s expression resulting in SIPS 
(Figure 10).  Recent data also provides another example of the involvement of p38MAPK in 
pathways that induce growth arrest in breast cancer cells. The growth factor activin depends on 
p38MAPK to induce growth arrest in breast cancer cell line T47D (Cocolakis, Lemay et al. 2001).   
 
 
Figure 10.  Schematic diagram of the Cav-1 gene promoter activated by oxidative stress.  Oxidative stress 
induces cellular changes that upregulate p38MAPK by phosphorylation.  The kinase activates transcription factor Sp1, 
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which binds to 2 GC-boxes in the Cav-1 promoter.  Finally, the Cav-1 protein is upregulated and mediates stress 
induced premature senescence. 
 
 
 Transcription factors promote protective effects against ROS by regulating transcription 
of genes whose products manage cellular damage (Lezoualc'h and Behl 1998; Post, Holsboer et 
al. 1998; Scortegagna, Galdzicki et al. 1999).  Here we show that Sp1 protects from ROS by 
binding to the Cav-1 promoter, leading to increased Cav-1 expression, which triggers SIPS. The 
Sp1 transcription factor, ubiquitously expressed in mammalian tissues, is a member of a family 
of DNA binding proteins that have 3 zinc finger motifs and bind to GC-rich DNA (Kadonaga, 
Carner et al. 1987; Courey, Holtzman et al. 1989).  Work by another group has shown that Sp1 
expression is related to Cav-1 and p53 expressio
 
 
 
ionophore-induced apoptosis (Jeong, Goo et al. 2008).  Sp1 binds to its promoter and repress 
SMP30 (Supakar, Fujita et al. 2000) ((Rath, Pandey et al. 2008).  Interestingly, SMP30 
n.  In MCF7 cells, exogenous expression of Cav-
1 increased Sp1 levels in p53 expressing cells but not in p53 null MCF7 cells, thus linking the 
three proteins (Glait, Tencer et al. 2006).  We have shown one mechanism of how Sp1 is 
involved in the induction of SIPS.  However, Sp1 regulates other tumor suppressor genes as well. 
For example connexins, the protein component of gap junctions, are implicated in tumor
suppression, as loss of communication via gap junctions appears to play a role in oncogenesis   
Sp1 binds to the Connexin 26 (Cx 26) GC-rich promoter and induces activation.  Cx 26 is a
structural component of gap junctions, and like Cav-1, is down regulated in breast cancer by 
methylation of its promoter, (Engelman, Zhang et al. 1999; Tan, Bianco et al. 2002). 
Sp1 can also inhibit the transcription of certain genes. Senescence marker protein-30 
(SMP30) enhances plasma membrane calcium pump activity and is protective against calcium 
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expression is shown to decrease in aging rat livers (Fujita, Shirasawa et al. 1998).  This example 
also fits with our model of senescence, or aging, in which Sp1 is upregulated.  A study on Sp1 
at 
ount of 
tim
then the tran
in older tissues, where there would be an accumulation of senescent cells, there could be overall 
Our results indicate the breast cancer epithelial cell line, MCF7 does not undergo SIPS 
when e
sult (Figure 11).  When 
Cav-1 
and aging shows that with age there is an inverse correlation between Sp1 DNA-binding activity 
and total protein expression in old versus young rats (Ammendola, Mesuraca et al. 1994).  This 
is intriguing in light of our results.  It must be noted that premature senescence is a process th
occurs in the young and old alike.  Oxidative damage up-regulates Sp1 and causes cellular 
senescence.  It is not known whether Sp1 activity remains elevated for an extended am
e after oxidative stress.  It is conceivable that Sp1 activates Cav-1 leading to senescence, but 
scription factor’s activity is not needed to maintain the senescence phenotype.  Thus, 
less Sp1 activity. 
xposed to hydrogen peroxide but alternatively undergoes apoptosis.  This is in contrast to 
normal mammary epithelial cells (HMEC), which undergo SIPS.  Even though MCF7 cells have 
a functional p53 protein, SIPS is still dependent upon Cav-1 expression. Cav-1 dependent SIPS 
is in multiple cell types (e.g. fibroblasts and epithelial cells), thus, illustrating Cav-1 is necessary 
for oxidatively induced SIPS. In the breast cancer Cav-1 null background, cells did not 
preferentially undergo SIPS, but instead undergo apoptosis.  Therefore, we hypothesize that Cav-
1 may function as a “senescence switch” in the presence of a cellular in
is present in a p53 wildtype background cells will undergo SIPS, and in the absence of 
Cav-1, cells will undergo alternative outcomes.  Our results demonstrating Cav-1 induced 
senescence and tumor suppression in MCF-7 cells has been supported by evidence in vivo in 
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which Cav-1 expression in MCF-7 cells decreased invasion and migration (Wu, Wang et al. 
2008), thus, suggesting Cav-1 acts as a tumor suppressor in these cells. 
 
Figure 11.  Schematic diagram of Cav-1 expression as a "senescence switch".  Data from MCF7 and HMEC 
cells show that when epithelial cells express Cav-1, after oxidative stress the cells will undergo SIPS.  However, 
cells in the Cav-1 deficient breast cancer cell line MCF7 preferentially undergo apoptosis. 
 
From a therapeutic standpoint, these data shed light on new targets for anti-aging. The 
absence of Cav-1 in MCF7 cells is advantageous for a non-aging phenotype.  Therefore, 
downregulation of the Cav-1 gene could possibly be a therapeutic target eliminating SIPS when 
it is deleterious to the organism. In addition to Cav-1, its upstream regulator, p38MAPK could be a 
target of anti-aging therapy as it is necessary for Cav-1 mediated SIPS.  Inhibitors of p38MAPK 
could block SIPS in response to oxidative damage. However, this could cause proliferation of 
cells harboring genetic mutations that could be harmful to the organism. 
Our research was done from the perspective that Cav-1 is downregulated in cancer and 
serves as a tumor suppressor.  There are examples, even in breast cancers, where Cav-1 is 
upregulated (Pinilla, Honrado et al. 2006; Garcia, Dales et al. 2007).  These are generally very 
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aggressive malignancies.  It could be that mutations have occurred during the transformation of 
the cells, which allowed them to overcome SIPS irrespective of Cav-1 expression. 
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4.0 CAV-1 MEDIATES SIPS THROUGH P53 UP-REGULATION BY 
SEQUESTRATION OF MDM2 
 
4.1 INTRODUCTION 
Caveolae, plasma membrane organelles, are 50-100 nm flask-shaped invaginations in the plasma 
membrane.  Caveolae are a subset of lipid rafts and are rich in cholesterol and sphingolipids 
making them Triton X-100 insoluble.  The Cav-1 protein is a structural component of caveolae 
membranes (van Deurs, et al. 2003).  Caveolae are present in a vast number of cells including 
fibroblasts, adipocytes, endothelial cells, type I pneumocytes, epithelial cells, smooth and striated 
muscle cells (Galbiati, et al, 2001).  The physiological roles of this microdomain vary among 
different cell types and organ systems (Razani, et al 2002).  For instance, caveolae function in 
endocytosis, transcytosis, cholesterol transport, homeostasis, positive and negative regulation of 
Ras-, NO-, G-protein coupled receptor-, and growth-factor mediated signaling (van Deurs, et al. 
2003).  Because of their low density and Triton X-100 insolubility, caveolae are easily isolated 
from the rest of the plasma membrane by treatment with mild nonionic detergents and sucrose 
ultracentrifugation.  The Cav-1 protein is used as a selective marker for caveolae and verifies 
isolation of the caveolae microdomain from the rest of the plasma membrane (Razani, et al 
2002).   
 76 
Cellular localization of signaling molecules is mediated by scaffolding proteins (Faux 
and Scott 1996). Cav-1’s cellular behavior is indicative of a scaffolding protein: Cav-1 forms 
multivalent homo-oligomers, most of the signaling molecules that interact with Cav-1 bind to the 
same site on the protein, and upon binding Cav-1 holds most signaling molecules in an inactive 
conformation (Li, Couet et al. 1996). The caveolin protein acts as a direct inhibitory scaffolding 
protein for numerous signaling molecules such as the G-protein α subunit, nitric oxide synthase 
(NOS), protein kinase C (PKC), and protein kinase A (PKA) (Garcia-Cardena, Oh et al. 1996; 
Li, Couet et al. 1996; Engelman, Zhang et al. 1998; Galbiati, Volonte et al. 1999; Razani, Rubin 
et al. 19
 lesions, 
and tre
99) There are a few exceptions to this, for example Cav-1 can stimulate the estrogen and 
insulin receptor signaling (Yamamoto, Toya et al. 1998; Schlegel, Wang et al. 2001).   The 
majority of proteins seem to bind to the caveolin scaffolding domain (CSD), which spans 
residues 82-101 (Li et al. 1995) within the membrane-proximal region.  Recently, work done 
with a cell permeable peptide of the CSD, deemed Cavtratin, shows that the minimal CSD can 
inhibit signaling molecules in vitro and in vivo.  These studies add strength to the argument that 
Cav-1 is a scaffolding protein, as the CSD is sufficient to see results, which the full length Cav-1 
protein would exhibit.  For example, there is down-regulation of Cav-1 in atherosclerotic
ating porcine arteries with Cavtratin inhibited the activity of enzymes associated with 
plaque instability (Rodriguez-Feo, Hellings et al. 2008).  Cav-1 null tumors exhibit hyper-
permeability and increased eNOS activity.  Treatment with Cavtratin inhibited eNOS and had 
antitumor effects (Gratton, Lin et al. 2003; Bauser-Heaton, Song et al. 2008).  Additionally, 
Lewis lung carcinoma cells injected into Cav-1 knockout mice show increased tumor vascular 
permeability and higher tumor growth rates.  Treatment of the knockout mice with Cavtratin 
attenuated tumor hyper-permeability and decreased tumor growth (Lin, Yu et al. 2007).  
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Furthermore, Cavtratin antagonizes the effects of siRNA knockdown of Cav-1 in brain 
microvascular endothelial cells (Song, Ge et al. 2007).  Lastly, Cav-1 can mediate tumor 
suppressor effects.  Use of the Cavtratin in metastatic PyMT mammary carcinoma cell line, 
MET, shows that Cavtratin is sufficient to inhibit invasion of these cells (Williams, Medina et al. 
2004). The proteins that bind to the CSD share common amino acid motifs, deemed the caveolin 
binding domain (CBD).  These sequences are variations of the following amino acid patterns ΦX 
ΦXXXX Φ, ΦXXXX ΦXX Φ or ΦXΦXXXXΦXXΦ, where X is any amino acid and Φ is an 
aromatic reside  (Couet et al. 1997a). 
Cav-1 inhibits signaling molecules associated with cell proliferation and is down-
regulated in many cancers. This association is supported by the fact that the Cav-1 gene is 
localized at chromosome 7q31.1, a region deleted in many human cancers.  These observations 
oma 
(Cantia
suggest Cav-1 acts as a tumor suppressor protein (Razani, et al 2002 and van Deurs, et al. 2003).  
Likewise, the Cav-1 gene is down-regulated in a myriad of cancers: breast adenocarcinoma, 
cervix carcinoma, lung small cell carcinoma, various mesenchyme sarcoma, ovary carcinoma, 
thyroid follicular carcinoma, vascular angiosarcoma (Williams and Lisanti 2005), osteosarc
ni, Manara et al. 2007), and mucoepidermoid carcinoma (Shi, Chen et al. 2007). 
While down regulation of Cav-1 is linked to cancer, high levels of Cav-1 are linked to 
cellular senescence.  Data from our laboratory and others distinguish the protein Cav-1 as a key 
mediator of SIPS in fibroblasts. Senescent cells are characterized by growth arrest.   Also, the 
cell morphology becomes larger and flatter, and expresses increased SA-β-Galactosidase activity 
(Cho, et al.  2003). Senescence is part of the natural aging process, and is a tumor-protection 
mechanism (Pelicci, 2004).  Cav-1 induces growth arrest (Galbiati, Volonte et al. 2001) and  
evidence for Cav-1’s growth inhibitory function is its overexpression causes transcriptional 
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repression of cyclin-D (Hulit, Bash et al. 2000) and knocking out Cav-1 causes upregulation of 
cyclin D1 levels (Williams, Cheung et al. 2003).  It has been shown that overexpression of Cav-1 
is sufficient to induce premature senescence in mouse embryonic fibroblasts. Likewise, 
endogenous Cav-1 expression is up-regulated in senescent cells (Volonte, Zhang et al. 2002), and 
the senescent phenotype is reversed by reducing Cav-1 expression with siRNA (Cho, Ryu et al. 
2003). Cav-1 is implicated in the signaling pathway triggered by oxidative stress, which leads to 
SIPS (Dasari, Bartholomew et al. 2006).  Oxidative stress induced premature senescence occurs 
through up-regulation of Cav-1.  Additionally, Cav-1 has been linked to p53 activation and the 
accumulation of its downstream target p21 (Volonte, Zhang et al. 2002). Furthermore, Cav-1 
may play a role in aging because the protein’s expression increases in aged tissues (Cho, Ryu et 
al. 2003).   
 Taken together, these data lead to the hypothesis that Cav-1 and the proteins interacting 
with it have the potential to disclose the link between aging and cancer.  Because aging and cell 
senescence seem to be a natural deterrent for cancer, knowing how aging is regulated and the 
proteins involved in the process will be important for developing effective cancer therapies. 
p53 is a known tumor suppressor activated by cellular stresses such as DNA damage, 
oxidative stress and oncogenic signals.  Once activated, p53 transcribes genes that allow the cell 
to go through apoptosis or growth arrest and senescence (Pelicci, 2004). p53 deters cells from 
passing on damaged DNA as the protein is the primary regulator of apoptosis, growth arrest and 
senescence.  Under normal, non-stressed conditions, p53 levels are kept low by its short half-life 
(5-30 minutes) by its negative regulator, MDM2 (Levine 1997; Wu and Levine 1997). The 
importance of MDM2’s regulation of p53 has been illustrated in knockout mouse models.  In 
MDM2 knockouts, embryos die before E6.5.  However, if MDM2 null mice are crossed with p53 
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knocko
e residues (Moll and Petrenko 
003).  MDM2’s E3 ligase activity is located in its C-terminal zinc binding RING finger domain.  
This domain transfers monoubiquitin tags to p53’s C-terminal (Honda, Tanaka et al. 1997; 
Kubbutat, Ludwig et al. 1998; Fang, Jensen et al. 2000).  Crystallographic data show that the p53 
transactivation domain binds in of MDM2, deterring p53’s interaction 
with transcriptional machinery. MDM2’s N-terminus interacts with the α-helix of the p53 N-
terminal transactivation domain (Kussie, Gorina et al. 1996), resulting in MDM2 repressing the 
transcriptional activity of p53 (Yang, et al. 2004(Oliner, Pietenpol et al. 1993).  When p53 needs 
to be expressed in response to oncogenic signaling, MDM2 is targeted by Ataxia telangiectasia 
mutated (ATM) for phosphorylation.  Modification by phosphorylation occurs in MDM2’s p53 
binding domain and central acid domain.  These domains are thought to be required for p53 
degradation, and thus blocking of these domains can lead to p53 activity (Hay and Meek 2000).  
Additional regulation of MDM2 is from p14 Alternative Reading Frame (ARF), which can bind 
to the RING finger domain of MDM2 and inhibit its E3 ligase activity (Honda and Yasuda 
1999). Interestingly, over-expression of caveolin -1 activates p53 (Galbiati et al., 2001b).  
uts, there is no lethality (Jones, Roe et al. 1995).  Interestingly, MDM2 is a target gene of 
the p53 transcription factor (Barak, Juven et al. 1993; Chen, Marechal et al. 1993; Picksley and 
Lane 1993).  The two proteins are involved in a negative autoregulatory feedback loop.  MDM2 
keeps p53 abundance low under non-stressful conditions and also limits biological responses 
after stress (Haupt, Maya et al. 1997; Kubbutat, Jones et al. 1997).  The MDM2 protein is an E3 
ubiquitin ligase and promotes p53 ubiquitination and degradation by nuclear and cytoplasmic 
26S proteasomes (Bottger, Bottger et al. 1997; Haupt, Maya et al. 1997; Maki 1999; Shirangi, 
Zaika et al. 2002).  Ubiquitination adds ubiquitin chains on lysin
2
the deep hydrophobic cleft 
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Data in chapter 3 shows that hydrogen peroxide induced oxidative stress stimulates a
signaling cascade that activates p38MAPK and its downstream target, the transcription factor Sp1. 
Sp1 binds to two GC-rich regions in the Cav-1 gene promoter and induces Cav-1 gene 
transcription.  The up-regulation of Cav-1 is followed by p53 up-regulation and induction of
SIPS (Dasari, Bartholomew et al. 2006).  How Cav-1 increases p53 activity leading to SIPS is 
not known.  We hypothesize that MDM2, the negative regulator of p53, is sequestered by Cav-1 
upon oxidative stress, decreasing MDM2’s ability to degrade p53, allowing the transcription 
factor to up-regulate cell cycle arrest genes and bring about SIPS. 
 
4.2 RESULTS 
4.2.1 Characterization of Sequestration of MDM2 by Cav-1 After Oxidative Stress 
4.2.1.1 Oxidative stress from hydrogen peroxide induces SIPS 
Subcytotoxic doses of hydrogen peroxide can induce SIPS in human and rodent fibroblasts.  To 
show that these doses induce SIPS in the human cell line WI-38 fetal lung fibroblasts, the cells 
were treated with 450 µM of hydrogen peroxide for 2 hours, were washed twice in 1X PBS and 
allowed to recover for 24 hours.  Immunoblotting shows that p53, p21 and Cav-1, all markers of 
SIPS, are up-regulated after hydrogen peroxide treatment (Figure 12A).  Following the 7 days of 
treatment, Senescence Associated–ß-galactosidase (SA- ß-galactosidase) activity staining was 
conducted to detect senescent cells.  Results in Figure 12B and C show that there is a 100-fold 
difference in SA- ß-galactosidase activity between treated and untreated groups. 
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Figure 1
were washed twice in 1X PBS and recovered for 24 hours.  Normalized cell lysates were subjected to SDS-PAGE 
and the resulting blots were probed with antibodies for p53, p21 and Cav-1.  (B) WI-38 human fetal lung 
4.2.1.2 MDM2 translocates to detergent resistant membranes after oxidative stress 
Caveolae are membrane invaginations that are a subclass of lipid rafts.  These lipid rafts are 
cholesterol and spingolipid rich areas that contain polymerized caveolin proteins.  Caveolins are 
membrane bound proteins that are palmitoylated and bind cholesterol (Dietzen, Hastings et al. 
1995; Murata, Peranen et al. 1995; Li, Song et al. 1996; Smart, Ying et al. 1996).  Therefore by 
isolating the caveolae, it is possible to isolate proteins that may be associated with caveolae and 
caveolins.  Caveolae are part of the class of detergent resistant membranes (DRMs), which will 
float to low densities in sucrose gradients.  Therefore, sucrose gradients are used to sort 
membranes by size or density and identify proteins with lipid raft association (Simons and 
Ikonen 1997; Brown and London 1998; Hooper 1999; Simons and Toomre 2000).  Caveolins are 
established protein markers of caveolae and can thus be used to determine isolation of the 
organelle.  Cav-1 and its associated proteins are Triton X-100 detergent resistant.  Therefore, in a 
sucrose gradient Cav-1, Flotillin-1 and other lipid raft associated proteins float in detergent 
insoluble fractions. This is normally at the interface between 5-30% sucrose. In a 12-fraction 
sucrose gradient, this would correspond to fractions 4, 5, and 6. If enough protein is present and 
the gradient has run properly, the lipid raft fraction also has a visible ring of insoluble proteins.  
2.  Oxidative stress induces SIPS in fibroblasts.  (A) Immunoblot analysis of proteins up-regulated in 
SIPS.  WI-38 human fetal lung fibroblasts were treated with 450 µM of hydrogen peroxide (H2O2) for two hours, 
WAF/CIP1 
fibroblasts were treated as listed in (A) and allowed to recover for 7 days.  Cells were subjected to SA–ß-
Galactosidase Activity assay according the manufacturer’s instructions (Cell Signaling).  Staining was analyzed 
using a BX50WI Olympus Optical light microscope at a magnification of 10X. A representative field is shown in 
(B). Quantification of the assay is shown in (C).  Values represent means ± SEM. *P<0.001.  
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A sucrose gradient was employed to determine whether oxidative stress caused 
movement of MDM2 into caveolae fractions from soluble fractions. Results in Figure 13 show 
that gradient separation was successful, because ± hydrogen peroxide both have Cav-1 in the 
insoluble fractions 4-6. Additionally, p53 is known to increase with oxidative stress (Volonte, 
Zhang et al. 2002). The immunoblot for p53 shows that under normal conditions p53 expression 
is undetectable.  However, there is a marked increase in the protein’s expression with oxidative 
stress, demonstrating that the hydrogen peroxide treatment activated distress signaling in these 
cells.  p53 is found in soluble fractions where nuclear proteins and other non-raft associated 
proteins reside.  There is an increase in MDM2 expression after hydrogen peroxide treatment 
attributed to the increase in p53. (p53 can induce MDM2 expression as part of its negative 
feedback loop for eliminating itself.) Figure 13 shows that under normal conditions, MDM2 is 
localized in soluble fractions (9, 10, and 11) along with p53.  However, after oxidative stress, 
After hydrogen peroxide treatment MDM2 is found in fractions where it can no longer localize 
MDM2 translocates to insoluble fractions (4, 5, and 6) where Cav-1 and lipid rafts are localized.  
with p53. 
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 Figure 13.  MDM2 translocates to caveolae-associated fractions of a sucrose density gradient upon hydrogen 
peroxide treatment. WI-38 fetal lung fibroblasts were treated ± 450 µM hydrogen peroxide (H2O2) for 2 hours, 
washed twice with 1X PBS and allowed to recover for 24 hours in regular growth media.  Samples were subjected to 
sucrose density centrifugation by layering 40-5% sucrose and centrifuging for 16 hours.  12 fractions were collected 
from the top of gradient with the first one considered fraction one. Non-caveolae (fractions 9-11) and caveolae 
(fractions 4-6) fractions were analyzed using SDS-PAGE immunoblot analysis with antibodies for anti-MDM2, anti-
p53 and anti-Cav-1.  Data is representative of three independent experiments. 
4.2.1.3  MDM2 localizes with Cav-1 after hydrogen peroxide induced oxidative stress 
Sucrose gradient centrifugation showed that MDM2 translocates into Cav-1 associated lipid rafts 
after oxidative stress. Immunofluorescence microscopy was conducted to directly assess the 
location of MDM2 before and after oxidative stress. WI-38 fetal lung fibroblasts were treated ± 
hydrogen peroxide and 48 hours later staining for MDM2, p53, and Cav-1. Results from Figure 
14A and Figure 14B show oxidative stress induced increases in Cav-1 and p53 protein 
expression, which agree with previous observations (Volonte, Zhang et al. 2002).  In untreated 
cells, MDM2 co-localizes with p53 in the nucleus (Figure 14B).  However, upon treatment, p53 
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intens rane 
com  
. 
me
ity in the nucleus increases and MDM2 signal translocates to the cytoplasm and memb
of the cells. Results from Figure 14 also show that MDM2 re-localization causes a change in its 
partmentalization with p53; it is no longer predominantly co-localized with p53. 
Additionally, in Figure 14A we see that with hydrogen peroxide induced oxidative stress, Cav-1 
expression increases and, like MDM2, is also localized to the membrane and the cytoplasm
Following hydrogen peroxide treatment, there is movement of MDM2 from the nucleus to the 
mbrane and cytoplasm where it is co-localized with Cav-1.  
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 Figure 14 8 fetal lung 
fibroblast rs, washed 
twice with ected to 
.  MDM2 co-localizes with Cav-1 after hydrogen peroxide induced oxidative stress. Wi-3
s were cultured on glass coverslips, treated with ± 450 µM hydrogen peroxide (H2O2) for 2 hou
 1X PBS and allowed to recover for 24 hours in conditioned media. Cells were subj
immunohistochemistry 48 hours after treatment.  Cells were fixed with formaldehyde, permeabilized with Triton X-
100 and co-stained with MDM2 and Cav-1 antibodies (A) or MDM2 and p53 (B) and visualized with fluorescent 
secondary antibodies.   Control cells were not treated (CTL). Arrows show areas of co-localization.  The asterisk 
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shows an area where MDM2 and Cav-1 co-localize in the cytoplasm.  Images were taken on a Zeiss confocal 
microscope. 
4.2.1.4 MDM2 plasmid construction 
ine In order to detect protein-protein interactions more readily, a c-Myc tagged construct of mur
MDM2 was created (WT-MDM2-cMyc).  Reverse transcription of mRNA from mouse lung 
tissue resulted in the corresponding cDNA.  Using common cloning techniques (see Methods for 
details), MDM2 was ligated into the pCAGGS vector.  Figure 15 shows the protein is expressed 
48 hours after transfection in NIH 3T3 fibroblasts.  The same cloning technique was utilized to 
make point mutations in MDM2 (ΦÎA-MDM2-cMyc) (see section 4.2.1.10).  The mutant 
protein is also expressed in NIH 3T3 fibroblasts 48 hours after transfection.  Both constructs 
were the appropriate molecular weight for the MDM2 protein. 
 
Figure 15.  Expression of c-Myc tagged MDM2.  The mouse MDM2 gene was cloned from murine lung tissue.  
Using common cloning techniques, it was c-Myc tagged and ligated into the pCAGGS vector. The sizes of the PCR 
products were consistent with the size of the gene (data not shown).  NIH 3T3 fibroblasts were transfected by 
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calcium phos alized for protein 
concentration  and anti-c-Myc 
antibodies show th
4.2.1.5 tment 
ent, MDM2 and 
Cav-1 co-lo M2 and Cav-1 associate 
stry experiments, 
monoclonal antibody to detect MDM2-c-Myc.  Resolution of the results was determined by 
immunoblot analysis for the proteins of interest. Data shows that there is hardly any interaction 
ent 
phate. Cells were lysed in boiling sample buffer 48 hours after transfection, norm
and subjected to SDS-PAGE and subsequent immunoblotting.  Anti-MDM2
at wildtype MDM2 and the mutant form are equally expressed. 
MDM2 and Cav-1 associate with one another after hydrogen peroxide trea
Immunofluorescence experiments show that upon hydrogen peroxide treatm
calize together at the plasma membrane.  To see whether MD
with one another under oxidative stress, as suggested by the immunohistochemi
a co-immunoprecipitation was conducted. NIH 3T3 cells were transfected with 15 μg of each of 
Cav-1 and cMyc-MDM2 constructs. After 24 hours, the cells were treated with 150 mM 
hydrogen peroxide for 24 hours, whereas the control group was not treated with hydrogen 
peroxide. Normalized cellular extracts were subjected to immunoprecipitation using a cMyc 
between MDM2 and Cav-1 before oxidative stress. However, after hydrogen peroxide treatm
there is a strong association between the two proteins. Immunoblotting of total cellular extract 
shows normalization of samples was achieved (Figure 16).  
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 Figure 16.  Hydrogen peroxide triggers association between MDM2 and Cav-1. NIH 3T3 cells were co-
transfected with 15 μg of caveolin-1 and MDM2-c-Myc constructs.  After 24 hours, the cells were treated with 150 
mM hydrogen peroxide (H2O2) for 2 hours, whereas the control group was untreated.  Normalized cellular extracts 
were subjected to immunoprecipitation using a cMyc monoclonal antibody.  (cMyc was appropriate because the 
MDM2 construct has a Myc tag.)  Immunoblot analysis anti-Cav-1 shows that the H2O2 treatment resulted in more 
interaction between the two proteins than the control group. 
4.2.1.6   Caveolin scaffolding domain is the minimal sequence necessary to bind MDM2 
Since the immunoprecipitation experiments show MDM2-Cav-1 association, we wanted to 
determine which amino acids on Cav-1 were necessary for the interaction.  A GST pull-down 
was conducted using GST-fusion proteins. Fusion proteins were made by fusing glutathione 
transferase (GST) with the full length Cav-1 protein, a shorter fragment of Cav-1 (amino acids 1-
101), and with the minimal Cav-1 scaffolding domain (amino acids 82-101).  The fusion proteins 
were affinity purified by binding to glutathione agarose beads. Figure 17A shows that the 
purified fusion proteins that were expressed have the correct predicted molecular weights.  The 
fusion proteins were incubated with cellular extract in which MDM2 was over-expressed.  
Denaturing the beads and conducting an immunoblot for MDM2 showed Cav-1 association.  
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Figure 17B, depicting the GST pulldown assay, shows MDM2 can bind to all of the GST-Cav-1 
fusions, and the minimal amino acid sequence necessary is amino acids 82-101.  This sufficient 
stretch of amino acids in Cav-1 corresponds to the caveolin scaffolding domain (CSD).  The 
control of GST only (not fused to Cav-1) did not show any association with MDM2.  This 
demonstrates absence of non-specific binding. 
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 ing full length 
 SDS-PAGE, 
and transferred to a nitrocellulose membrane.  Ponceau staining shows the correct size of the fusion proteins created 
highlighted by arrows (A).  GST alone or GST- Cav-1 deletion mutants were conjugated to glutathione-agarose 
Figure 17.  MDM2 binds to the Caveolin Scaffolding Domain.  GST-Cav-1 fusion proteins contain
Cav-1, amino acids 1-101, or only the CSD (amino acids 82-101) were affinity purified, subjected to
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beads and incubated overnight with cell lysate expressing exogenous MDM2-c-Myc.   Eluted proteins from the GST 
pull-down were resolved by SDS-PAGE and immunoblotted for c-Myc (B) to detect MDM2 binding.   
4.2.1.7  MDM2 contains a putative Caveolin Binding Domain (CBD) 
Many signaling molecules that bind to the CSD contain a CBD (Couet, Li. et al. 1997). A CBD 
is normally defined to be a sequence motif with aromatic amino acids separated by a variable 
amount of amino acids. Since MDM2 associates with Cav-1, a search of its amino acid sequence 
was conducted to determine whether it contains a putative CBD.    The amino acid sequences of 
of 
ed 
in 
one of the 2 determined p53 binding domains on MDM2, which stretches from amino acids 23-
108 in the MDM2 protein (Figure 18B).  
human and mouse MDM2 contain a putative CBD. Figure 18A shows potential CBD motifs that 
have been verified to be in other signaling molecules (Couet, Li. et al. 1997).  Evaluation 
MDM2’s amino acid sequence has shown that the protein contains one of these motifs locat
between amino acids 48-60: Y(6X)FY(3X)Y. Interestingly, this putative CBD is located with
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Figure 18.  Putative Caveolin Binding Domain in the amino acid sequence of MDM2.  MDM2 has a putative 
CBD located between amino acids 48-60. This is an area with aromatic resides, which corresponds to other CBD 
motifs found in other signaling molecules that bind to Cav-1. A list of other previously identified peptide ligands 
from screening phage-display libraries using a GST fusion protein containing the CSD is depicted.  Φ = aromatic 
residue (W, Y or F) and X= any amino acid (A).  A schematic of the MDM2 protein shows the CBD (residues 48-
60) is located within the p53 binding domain (residues 23-108) of MDM2 (B). 
 
e 
MDM2 protein and stimulate SIPS.  However, it is not known whether the putative CBD on 
MDM2 is necessary for the interaction with Cav-1.  To test the hypothesis that the putative CBD 
etween amino acids 48-60, a mutant 
MDM2 protein was made by PCR point mutation of specific nucleotides changing what would 
type 
4.2.1.8   Amino acids 48-60 on MDM2 are necessary for interaction with Cav-1 
The previously listed experiments determined that the CSD was sufficient to interact with th
in MDM2 stretches from the aromatic region of MDM2 b
be aromatic residues to alanines. The mutant was expressed at the same level as the wild
protein in NIH 3T3 cells (Figure 15).  To determine whether the mutated Φ→A MDM2-c-Myc 
had decreased interaction with Cav-1, a GST pull-down using GST fused to the caveolin 
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scaffolding domain CSD was conducted. Results in Figure 19 show that when equal amounts of
wildtype and mutant Φ→A MDM2 are expressed, the mutant ceases to bind to the CSD.  
 
 
 
Figure 19.  MDM2 with a mutated CBD does not associate with the CSD.  Mutant MDM2 was constructed from 
the wildtype MDM2 template by PCR point mutation.  A GST-CSD fusion protein was utilized in a GST pull-down 
assay.  GST alone or fused GST-CSD was conjugated to glutathione sepharose beads.  NIH 3T3 fibroblasts were 
overnight and eluted proteins were resolved by SDS-PAGE and immunoblotting for anti-c-Myc to detect MDM2. 
 
transfected with 30 µg of wildtype (WT) or mutant (Φ→A) MDM2.  Twenty-four hours later the cellular extracts 
were normalized based on MDM2’s expression.  Cellular extracts were incubated with the GST fusion beads 
4.2.1.9 Cav-1 can compete with p53 for MDM2 binding 
Figure 19 demonstrates MDM2 contains a CBD.  This domain is situated within amino acid 
residues 48-60.  Interestingly, this falls within one of p53’s binding domains on MDM2 (amino 
acid residues 23-108).  Since the CBD is located within the p53 binding domain, it is 
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hypothesized that Cav-1 should compete with p53 for MDM2 binding.  To test this hypothesis a 
competition assay between p53 and Cav-1 was conducted for MDM2 binding.  NIH 3T3 
fibroblasts were transfected with DNA by calcium phosphate in the following combinations:   
p53 10 µg 10 µg 10 µg 
MDM2 10 µg 10 µg 10 µg 
Cav-1 0 µg 1 µg 5 µg 
pCAGGS Vector 10 µg 9 µg 5 µg 
 
Forty-eight hours later, an immunoprecipitation was conducted using c-Myc to pulldown 
MDM2-c-Myc associated proteins.  Results were resolved by immunoblot analysis of Cav-1 and 
p53.  
    Figure 20 depicts total normalized cell lysate showing that the amount of Cav-1 DNA 
transfected was proportional to the protein's expression.  Additionally, with increased Cav-1 
expression, there is increased p53 expression in the normalized total cellular extract, even though 
equal amounts were transfected in each sample (see totals).  This is to be expected based on 
Results show that with minimal Cav-1 present, MDM2 has a strong association with p53.  As the 
amount of Cav-1 is increased there is disassociation between MDM2 and p53, with increasing 
association between MDM2 and 
previous findings that Cav-1 overexpression increases p53 levels (Galbiati, Volonte et al. 2001). 
Cav-1 (Figure 20).  
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 Figure 20.  Cav-1 and p53 compete for the binding of MDM2.  NIH 3T3 fibroblasts were transfected using a 
expression are shown in lower panels. 
standard calcium phosphate method with equal amounts of p53 and MDM2-Myc constructs. Additionally, 
increasing amounts of the Cav-1 construct were also transfected.  Forty-eight hours after transfection, an 
immunoprecipitation using anti-c-Myc was done to see if the interaction between p53 and MDM2 would vary in the 
presence of different amounts of Cav-1. An immunoblot was done with anti-p53 and anti-Cav-1 to detect p53 
binding to MDM2. Results show that Cav-1 competes for binding of MDM2 with p53.  Total Cav-1 and p53 
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4.2.1.10 The Caveolin Scaffolding Domain is sufficient to increase p53 activity leading 
to senescence 
Increased Cav-1 expression is correlated with SIPS.  Overexpression of Cav-1 is known to 
induce growth arrest (Galbiati, Volonte et al. 2001; Kawabe, Grant et al. 2001) and amplified 
expression of Cav-1 is found in aging tissues (Kawabe, Grant et al. 2001).  It is not known, 
however, whether it is the protein’s presence or the caveolae organelle that is responsible for 
mediating SIPS.  Our previous experiments indicate that it is Cav-1’s binding to MDM2 that 
mediates the senescence effect after oxidative stress. Cavtratin was utilized to distinguish 
whether the caveolae organelle, the full-length Cav-1 protein, or the CSD are necessary to induce 
SIPS.  Cavtratin is a cell-permeable peptide consisting of the CSD 
(CSDDGIWKASFTTFTVTKYWFYR) fused to the C-terminus of the internalization sequence 
of the Drosophila transcription factor antennapedia (AP) by Fmoc chemistry, purified and 
analyzed by reversed-phase HPLC and mass spectrometry by the Tufts University Core Facility. 
Detection of the peptide is made possible by a biotin tag followed by an aminohexanoic acid 
spacer added to the amino terminus of the AP fusion peptide.  Cavtratin can mimic the inhibitory 
effects of Cav-1 on signaling molecules.  Cavtratin does not form caveolae as it cannot 
oligomerize with the full-length protein.   Therefore, it is suitable to determine whether the CSD 
is sufficient to induce the SIPS effects of Cav-1. It was hypothesized that the CSD would 
upregulate p53 activity based on the results that it decreased interaction between p53 and its 
negative regulator MDM2 leading to p53’s stability.  A luciferase assay utilizing the p53 
responsive element was conducted to determine whether the CSD or the caveolae organelle is 
responsible for the upregulation of p53.  NIH 3T3 murine fibroblasts were transfected with the 
luciferase p53 responsive element and ß-galactosidase for sample normalization.  The next day 
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samples were treated with 10 µM of cavtratin or AP for 24 hours.  Results from the luciferase 
assay demonstrate that CSD upregulates p53 1.3 times more than AP alone does (Figure 21A).  
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fibroblasts were transfected with the 3 µg of both the p53 responsive element along with β-galactosidase to 
Associated-β-Galactosidase activity after 7 days.  Cells were observed under a BX50WI Olympus Optical light 
Figure 21.  The CSD is sufficient to upregulate SIPS.  A luciferase assay measuring the activity of the p53
responsive element upon treatment of 10 µM Cavtratin or AP for 24 hours was conducted.  NIH 3T3 murine 
normalize all samples.  After 24 hours, cells were treated with 10 µM Cavtratin or AP for an additional 24 hours and 
the luciferase activity was determined.  Values represent means ± SEM.  *P<0.01 (A).  WI-38 human fibroblasts 
were treated with 10 µM Cavtratin or AP for 24 hours.  An immunoblot assay was conducted to determine the 
expression of p21WAF/CIP1, a cyclin dependent kinase inhibitor.  Immunoblotting with anti-ß-actin IgGs show cell 
extract normalization (B). WI-38 cells were treated with 10 µM Cavtratin or AP and stained for Senescence 
microscope at a magnification of 10X.  Since AP treated cells continue to grow, samples were normalized based on 
cell number.  Quantification of the SA-β-Galactosidase positive cells is shown (C).  Values represent means ± SEM.  
*P<0.001. 
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This increased p53 activity led to up-regulation of downstream factors.  It was found that 
p21WAF/CIP1, p53’s downstream target, was upregulated 24 hours after cavtratin treatment (Figure 
21B). If the CSD is sufficient to block interaction between p53 and MDM2, then it should 
increase senescence.  Using SA β-galactosidase activity assay, it was also found that 10 µM 
cavtratin treatment is sufficient to induce premature senescence in WI-38 fibroblasts after 7 days 
(Figure 21C).  After adjusting for total cell number (non-senescent cells continue to proliferate) 
the cavtratin treated group contained four times more senescent cells than the AP only group did. 
 
4.2.2 SIPS is Dependent Upon Cav-1 
4.2.2.1 Cav-1 null mouse embryonic fibroblasts do not undergo SIPS after oxidative stress 
Increased expression of Cav-1 induces SIPS (Volonte, Zhang et al. 2002) and our studies show 
that the CSD stimulates SIPS.  However, it is not known whether SIPS triggered by oxidative 
stress is dependent upon Cav-1 expression in fibroblasts.  To determine if Cav-1 is necessary for 
SIPS, a null Cav-1 mouse embryonic fibroblast (MEFs) model was utilized.  MEFs were derived 
from Cav-1 wildtype (WT) and Cav-1 knockout (KO) mice.  The cells were cultured at the 
youngest passages possible (p3-5) and treated with 150 μM hydrogen peroxide for 2 hours and 
allowed to recover for a time course of 3, 5, 6, 8 or 10 days before SA-β-Galactosidase activity 
was quantified (Figure 22A). Data was quantified by counting the number of SA-β-Galactosidase 
positive cells and adjusting for cell number between the samples, as the KO MEFs continue to 
grow even after treatment with oxidative stress.  This was done by multiplying the ratio of the 
number of total WT and KO cells to the number of WT positive cells, to get the number of 
positive cells if the cell number were equal.  Even though the same numbers of WT and KO cells 
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were treated with hydrogen peroxide, data from Figure 22 shows that the knockout cells 
continued to proliferate and the wildtype did not.  Beginning 5 days after hydrogen peroxide 
treatment, there is a divergence in the amount of senescent cells between WT and Cav-1 KO 
MEFs.  By 10 days after treatment the difference is greatest with 10 times more senescent cells 
in the wildtype than in the knockout. 
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 Figure 22. Cav-1 knockout mouse embryonic fibroblasts do not undergo SIPS upon oxidative stress 
treatment.  MEFs were derived from C57B pregnant mice.  Embryos were screened for genotype, and fibroblasts 
were derived and cultured.  (A) Wildtype (WT MEFs) and Cav-1 knockout (CAV-1 KO MEFs) were treated with 
150 µM of hydrogen peroxide for 2 hours, rinsed twice with 1X PBS and allowed to recover for 0, 3, 5, 6, 8 or 10 
days before SA-ß-Galactosidase activity staining was conducted according to manufacturer’s instructions.  Cells 
were observed under a BX50WI Olympus Optical light microscope at a magnification of 10X.  Quantification of the 
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SA-ß-Galactosidase activity assay is shown in (A).  A representative field from 5 days after oxidative stress is 
shown in (B). 
4.2.2.2 p53 expression is decreased in hydrogen peroxide treated Cav-1 null MEFs 
It was hypothesized that the decreased senescent phenotype in the Cavoelin-1 KO MEFs may be 
due to the absence of senescence inducing proteins.  Because p53 is increased in the presence of 
Cav-1, its expression was analyzed in the absence of Cav-1.  Immunoblotting was conducted to 
determine the expression of p53 and p21 after oxidative stress in WT and Cav-1 KO MEFs.  In 
Figure 23A, results show that after 48 hours the expression of p53 increased in the WT, but not 
in the KO MEFs.  Also at this same time point, p53’s downstream target p21 increased more in 
the WT than in the KO. 
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    WT and Cav-
1 KO MEFs were treated with 150 µM of hydrogen peroxide (H2O2) for 2 hours, rinsed twice with 1X PBS and 
on 
ß-actin showed equal loading (A).  An immunoprecipitation was conducted on samples 12 and 48 hours after 
Figure 23.  Without sequestration of MDM2 by Cav-1 the expression of p21 and p53 decreases.
allowed to recover for 48 hours in regular media.  An immunoblot analysis of Cav-1, p53 and p21WAF/CIP1 expressi
shows that the proteins are upregulated 48 hours after oxidative stress in the WT MEFs.  Immunoblotting with anti-
oxidative stress.  Anti-MDM2 conjugated Sepharose A beads were mixed with cellular extract overnight.  SDS-
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PAGE was done to resolve the proteins and anti-p53 and anti-Cav-1 IgGs were used to determine association with 
MDM2 (B). 
4.2.2.3 Decreased p53 associated with MDM2 in Cav-1 null MEFs 
It is hypothesized that in Cav-1 knockouts, the decreased p53 and subsequent p21 expression is 
because Cav-1 is not present to sequester MDM2.  Thus, MDM2 will remain associated with 
determ .  
lls 
 MEFs 
hydrogen peroxide treatment.  Moreover, because of the association between MDM2 and p53, 
 would be less p53 expression in the KO than in the WT (Figure 23A). Additionally, in the 
WT, after oxidative stress, there is increased association between Cav-1 and MDM2, which is 
inversely proportional to the interaction between p53 and MDM2 (Figure 23B). 
4.2.2.4   p53 reduction in Cav-1 knockout MEFs is due to proteasomal degradation 
p53, leading to the transcription factor’s degradation and inhibition of SIPS.  To test this 
hypothesis, 12 and 48 hours after oxidative stress, an immunoprecipitation was conducted to 
ine the interaction between p53, MDM2 and Cav-1 in WT and Cav-1 KO MEFs
Sepharose A beads conjugated to MDM2 IgGs were utilized to bind to endogenous protein. The 
untreated WT MEFs show that there is very little expression of p53 and therefore little binding 
between the two proteins.  This is expected as previous experiments show untreated control ce
have very little p53 expression.  Results show that after hydrogen peroxide treatment, WT
exhibit only slight interaction between p53 and MDM2 even though there is upregulation of p53 
in contrast to the Cav-1 null MEFs (Figure 23A and B).  Without Cav-1 present to block their 
interaction, MDM2 and p53 have a stable interaction in the KO MEFs even 48 hours after 
there
Evidence from immunoprecipitations on Cav-1 knockout MEFs indicates that the continued 
association between MDM2 and p53 after oxidative stress leads to p53’s subsequent proteosomal 
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degradation by MDM2’s ubiquitination.  To determine whether the decreased p53 expression 
occurs at the transcriptional level or the protein level, the proteasomal inhibitor MG132 was 
utilized.  Eighteen hours after hydrogen peroxide treatment, cells were treated with MG132 for 6 
hours and lysed.  Immunoblot analysis of normalized cellular lysates shows that there is an 
accumulation of p53 and p21 as compared to the vehicle alone (Figure 24).   
 
Figure 24.  p53 and p21 in Cav-1 null MEFs undergo proteasomal degradation.  Cav-1 KO MEFs were treated 
th 1X PBS and allowed to recover for 18 hours in normal 
media.  T
4.3 DISCUSSION 
with 150 µM of hydrogen peroxide, washed twice wi
he MEFS were treated with 5 µM of the proteosomal inhibitor MG132 or the equivalent of vehicle DMSO 
for 6 hours.  Cells were lysed and an immunoblot analysis was done to determine the expression of proteins p53 and 
p21. 
The tumor suppressor protein p53 has been implicated as a keeper of the genome.  Well known 
for its role as a deterrent for cancer, it is now becoming a major player in organismal longevity 
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as well.  The transcription factor works to reduce somatic mutations and deter the proliferation of 
transformed cells. This highlights its role as a decision maker in cellular senescence, organismal 
aging and longevity (Campisi 2003; Vijg and Suh 2005; Kuningas, Mooijaart et al. 2008). Once 
p53 is activated by DNA damage it can direct a cell to one of 4 decisions to effect its fate and 
potentially the fitness of the organism: 1) transient arrest to try to fix the DNA damage.  If repair 
is done
iquitin-mediated degradation (Momand, Zambetti et 
al. 199
ce in human and primary murine fibroblasts, transformed fibroblasts, and 
fibrosarcoma cell lines (Efeyan, Ortega-Molina et al. 2007; Kumamoto, Spillare et al. 2008).  
 properly there is no deleterious effect to the organism, however, improper repair can 
cause mutations in the DNA leading to cancer.  2) Apoptosis, which eventually leads to 
decreased tissue integrity from cellular depletion and to aging.  3) Senescence, which can 
decrease tissue renewal and alter tissue microenvironment leading to aging.  4) Or defective p53 
activity leads to its failure as a tumor suppressor resulting in somatic mutations that can 
potentiate cancer (Rodier, Campisi et al. 2007). Therefore, p53 has been implicated in 
organismal aging (Tyner, Venkatachalam et al. 2002; Maier, Gluba et al. 2004).  These findings 
and others show that the loss of p53 increases carcinogenesis risk (Christensen and Wallace 
1976; Malkin, Li et al. 1990; Donehower, Harvey et al. 1992; Frebourg, Kassel et al. 1992) and 
establish that p53 links aging and cancer. 
p53 half-life is mediated by the E3 ubiquitin ligase MDM2.  MDM2 binds and inhibits 
p53 activation by tagging the protein for ub
2; Haupt, Maya et al. 1997; Honda, Tanaka et al. 1997; Kubbutat, Jones et al. 1997; 
Midgley and Lane 1997; Giaccia and Kastan 1998).  A recent report shows Nutlin-3A, a small 
molecular antagonist of MDM2, can promote senescence.  In the presence of functional p53, 
Nutlin-3A can bind in the p53 binding pocket of MDM2, blocking its interaction with p53 and 
inducing senescen
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This work illustrates that p53-dependent senescence requires a blockage in the interaction of p53 
and MDM2.  Until now it was not known whether, with a synthetic inhibitor not present, what 
could trigger the break in interaction of p53 and MDM2 under normal cellular circumstances.  
We present Cav-1 as a mediator of cellular senescence by sequestering MDM2 after oxidative 
stress to allow for p53 upregulation and subsequent senescence.  
Previous work implicates Cav-1 as having a role in p53-mediated senescence.  Cav-1 
arrests cells in the G(0)/G(1) phase of the cell cycle. Transgenic mice over-expressing Cav-1 have 
primary cells with a reduced DNA replication rate and cell proliferation.  Furthermore, the over-
expression of Cav-1 can induce p53 activity (Galbiati, Volonte et al. 2001), and overexpression 
of Cav-1 in mouse embryonic fibroblasts induces senescence (Volonte, Zhang et al. 2002).  
Oxidative stress such as UV irradiation or hydrogen peroxide treatment actually upregulates 
upon oxidative stress p38  is activated and stimulates Sp1, which binds to the Cav-1 gene 
promoter at 2 GC-rich regions.  This up regulates Cav-1 and there is a subsequent increase in p53 
activity leading to SIPS (Dasari, Bartholomew et al. 2006
Cav-1 and p53 leading to stress induced premature senescence.  Our investigations show that 
MAPK
). This study focused on MDM2 and 
whether it was the link between caveolin-1 and p53 activi because of the aforementioned Nutlin 
3A studies and MDM2 containing a CBD.  
Our results show that after oxidative stress MDM2 translocates to caveolar fractions, and 
is sequestered by Cav-1.  This re-compartmentalization from the nucleus to the cytosol and 
plasma membrane where Cav-1 is located breaks the interaction between MDM2 and p53.  
Without p53 being degraded by MDM2, it can activate is downstream target p21 and induce 
SIPS (Figure 25). 
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 MAPK
binding of Sp1 to GC-rich boxes in the caveolin-1 gene promoter (B), and results in the upregulation of Cav-1 (C).  
As previously demonstrated by our laboratory, the upregulation of Cav-1 is correlated with the activation of p53 and 
IPS.  H
a competitor for binding between MDM2 and p53.  Hence, when MDM2 is sequestered to Cav-
Figure 25.  The proposed mechanism whereby Cav-1 mediated activation of p53 causes SIPS.  The previous 
chapter’s results show that p38  is phosphorylated and activated by oxidative stress (A).  This leads to the 
S owever, the mechanism by which Cav-1 influences p53 was still unknown (?).  Data from this chapter 
supports the hypothesis that MDM2 is sequestered by Cav-1, which allows p53 to become activated, thereby 
regulating downstream effectors such as p21, which induces SIPS (E). 
 
 
Our results show that MDM2 contains a CBD, which is necessary for its interaction with 
Cav-1.  Unfortunately, experiments to determine whether the mutated CBD in MDM2 was 
sufficient to abrogate SIPS were not possible.  Brown et al. shows that the Mdm2 gene expressed 
in non-neoplastic cells induces cell cycle arrest (Brown, Thomas et al. 1998).  Therefore, we 
could not stably express our mutant MDM2 to determine its effects on SIPS.  Interestingly 
though, MDM2’s CBD is located in the p53 binding domain of MDM2.  This sets Cav-1 up to be 
 110 
1, it can no longer interact with p53 allowing for increased activity of the transcription factor.  
Since MDM2 is an E3 ubiquitin ligase, it was a possibility that by its sequestration in the 
caveolae, it could interact with proteins residing there that would inhibit senescence.  Thus by 
tagging these proteins for degradation, it is positively influencing the SIPS phenotype.  To 
determine whether the caveolae organelle was necessary for the sequestration of MDM2 leading 
to SIPS, the cell permeable CSD, Cavtratin, was utilized.  We show that cavtratin is sufficient to 
 
a
Our studies in a Cav-1 null background shed light on how cancer cells can overcome senescence 
have the problem of p53 
instability from its regulators ARF/MDM2. (Sharpless 2005; Vousden and Prives 2005).  
induce senescence by decreasing interaction between p53 and MDM2 and by increasing p53 
activity leading to senescence.  Thus, only the CSD, which is the minimal sequence necessary to 
bind MDM2, and not the caveolae, is needed.  Our data with cavtratin mediating SIPS 
complements previous work, which shows that cavtratin, is sufficient to abrogate invasion of 
metastatic PyMT mammary carcinoma cell line Met-1 (Williams, Medina et al. 2004).  It is an 
example of how Cav-1 can act as a tumor suppressor. 
 The work in Cav-1 null MEFs confirms the hypothesized mechanism that Cav-1 mediates 
senescence by sequestering MDM2 to allow for increased p53 activity (Figure 26).  Additionally, 
it shows that in the absence of Cav-1, p53 is degraded and thus unable to initiate the signaling 
pathway to induce senescence.  This data is in agreement with previous findings in the field. 
Cho et al. showed that by knocking down Cav-1 expression with siRNA, the SIPS phenotype 
could be reversed as evidenced by: DNA synthesis, re-entry of senescent cells into cell cycle 
upon epiderm l growth factor stimulation, and decreases in p53 and p21 (Cho, Ryu et al. 2003).  
in their transformation.  It is estimated that 50% of all malignancies have a mutated p53 gene 
(Toledo and Wahl 2006).  Malignancies with functioning p53 may 
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Additionally, many cancers exhibit downregulated Cav-1 (Williams and Lisanti 2005).  From our 
results we speculate that cancer cells having wildtype p53 and downregulated Cav-1 cannot 
senesce because p53 is being inactivated by MDM2. Our work with MCF7 cells shows that 
hydrogen peroxide treatment does not induce SIPS.  When Cav-1 is re-introduced by adenovirus 
infection, the SIPS phenotype is restored supporting the claim of Cav-1 being a tumor 
suppressor. 
 
Figure 26.  Schematic diagram recapitulating oxidant-induced Cav-1 dependent activation of the 
treatment induces oxidative stress triggering the p53 pathway leading to SIPS by Cav-1 sequestering p53’s negative 
regulator, MDM2.  This allows for decreased degradation of p53 allowing it to activate its downstream target
p53/p21WAF/CIP1 pathway and initiation of SIPS in fibroblasts.  Using MEFs, we show hydrogen peroxide 
 p21 
and induces SIPS.  In the absence of Cav-1, even after oxidative stress, there is still great association between p53 
and MDM2 leading to p53’s degradation and inhibition of SIPS in these fibroblasts. 
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5.0 THE ANTAGONIST PLEIOTROPIC EFFECTS OF CAVEOLIN-1 
 et al. 2003). And 2) the obvious observation 
that cen
 
5.1 INTRODUCTION 
In 1957 George Williams published the idea of the antagonistic pleiotrophy theory of 
aging.  He believed that some genes have a pluralistic effect of phenotypes, which could affect 
the organism differently depending upon the age of the organism.  For instance, a gene can have 
a positive effect by being protective early in life increasing the health and fitness of the 
organism, but it may become negative over time leading to aging and organismal death 
(Williams 1957). More recently, data has emerged establishing a link between aging and cancer. 
Blagosklonny et al. points out two pieces of evidence demonstrating that systemic aging is linked 
to increased cancer: 1) Studies that show caloric restriction increases life expectancy and 
decreases the incidence of cancer (Klurfeld, Weber et al. 1987; Grasl-Kraupp, Bursch et al. 1994; 
Muskhelishvili, Hart et al. 1995; Hursting, Lavigne
tenarians have a very low incidence of cancer as well as animal studies that show long-
lived mice have decreased cancer compared to shorter lived mice (Anisimov, Zabezhinski et al. 
2001; Ikeno, Bronson et al. 2003; Caruso, Lio et al. 2004; Blagosklonny and Campisi 2008). 
The senescence field suggests SIPS is a form of antagonistic pleiotropy.  Cells 
responding to damage can undergo senescence and thus avoid abnormal proliferation, which 
would have deleterious effects to the organism.  When the organism is young, this has a positive 
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effect allowing for reproduction and a high level of fitness.  However, with time, an 
accumulation of senescent cells becomes harmful as they change the tissue microenvironment, 
and inhibit adequate repair.  Interestingly, senescent fibroblasts cause the proliferation of 
transformed epithelial cells (Krtolica, Parrinello et al. 2001; Parrinello, Coppe et al. 2005; Liu 
and Hornsby 2007; Coppe, Boysen et al. 2008).  Judith Campisi has coined the phrase “Good 
citizens and bad neighbors” to desc ts.  She reasons that whatever cellular 
insult causes a fibroblast to senesce will also cause mutations in surrounding cells such as 
epithelial cells.  For a time, senescence has positive effect on the fibroblast stopping it from 
passing on its damaged or mutated genome.  However, the prematurely senescent fibroblast will 
start to secrete growth factors, cytokines, extracellular matrix and matrix metalloproteases that 
disrupt the surrounding microenvironment (Campisi 1997; Rinehart and Torti 1997; Kang, Chen 
et al. 2008). The changing stroma can cause pre-neoplastic and transformed epithelial cells to 
become neoplastic and prime the environment for their growth advantage (Campisi 2005).  
Evidence of senescence having antagonistic pleiotropic effects is that there is an increased cancer 
risk with age.  Statistics show that 60% of cancers and 70% of cancer mortalities occur in 
individuals 65 and older (Yancik and Ries 2000).  Additionally, the majority of age-related 
cancers arise from epithelial cells (DePinho 2000). 
Recent data shows that prematurely senescent fibroblasts induce proliferation of breast 
cancer cells in vitro and in vivo (Krtolica, Parrinello et al. 2001; Liu and Hornsby 2007).  
However, there is still much to be known about how senescent cells regulate the antagonistic 
pleiotropic effect on neoplastic epithelial cells.  Since we have shown that Cav-1 is necessary to 
induce p53 dependent SIPS, we hypothesize that it will play an integral role in the antagonistic 
pleiotropic effects of senescent fibroblasts on epithelial cells.  To study the effects of Cav-1 on 
ribe senescent fibroblas
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the antagonistic pleiotropic effects of senescent fibroblasts, we utilized wildtype (WT MEFs) and 
Cav-1 null mouse embryonic fibroblasts (KO MEFs).  We hypothesize that without Cav-1, 
MEFs treated with oxidative stress will not stimulate the growth of transformed cells.   
5.2 RESULTS 
5.2.1 NIH RasG12V transformed fibroblasts undergo SIPS when Cav-1 is re-expressed  
To determine the role of Cav-1 in antagonistic pleiotropy, we first wanted to determine how the 
presence of Cav-1 would effect cancer cells and whether its expression in senescent fibroblasts 
would effect the growth of cancer cells.  NIH RasG12V are a transformed fibroblast cell line 
known to have a downregulated Cav-1 expression (Engelman, Wycoff et al. 1997). When Cav-1 
was re-expressed in NIH RasG12V by transfection with a selection vector pCB7 for hygromycin, 
the transformed fibroblasts underwent senescence (Figure 27).  Results from quantification of the 
number of SA-β-galactosidase positive cells show approximately a 5-fold increase over vector 
only expressing cells.   
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 Figure 27.  Re-expression of Cav-1 in NIH 3T3 RasG12V rescues the SIPS phenotype.  (A) Cav-1 and pCB7, a 
ected by calci H 3T
analysis using anti-Cav-1 antib ies to detect the protein’s expression. Anti-β-actin IgGs were used in the 
immunoblot analysis to determine equal loading of samples (A).  In addition, cells were cultured in media 
containing 200μg/mL hygromycin for 14 days to select for Cav-1 or pCAGGS expressing cells.  Cells were 
vector carrying hygromycin resistance, were transf um phosphate into NI 3 RasG12V cells. 
pCAGGS (vector alone) was transfected as a control.  After 48 hours transfected cells were subjected to immunoblot 
od
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subjected to the senescence associated-βgalactosidase activity assay. Cells were observed with a BX50WI Olympus 
Optical light microscope at a magnification of 10x.  Quantification of the SA-β-galactosidase activity assay is 
*P<0.
5.2.2 Cav-1 expressing senescent MEFs induce proliferation of NIH 3T3 RasG12V 
transformed fibroblasts in vitro 
shown. Values represent means ± SEM. 001. 
 
Previous experiments from section 4.2.2, determined that Cav-1 is necessary for MEFs to 
undergo SIPS.  Thus, these wildtype and knockout Cav-1 cell lines were used to determine 
whether Cav-1 mediated SIPS is necessary to induce proliferation of transformed fibroblasts.  
Wildtype and Cav-1 knockout MEFs were treated with 150 μM hydrogen peroxide for 2 hours 
and recovered for 4 days.  MEFs along with RasG12V cells were serum starved for 3 days (thus, all 
cells were growth arrested) and co-cultured together.  7 days later cells were stained with DAPI 
to quantify the number of RasG12V cells.  Observation of light phase microscopy and UV settings 
show that MEFs have larger nuclei than RasG12V cells and are distinguished accordingly (data not 
shown).  Interphase marker, Ki67 was used to quantify the number of proliferating RasG12V cells.  
Quantification was conducted by counting the number of RasG12V nuclei by DAPI staining and 
positive Ki67 cells in 30 random fields and are reported in the relative number of DAPI positive 
RasG12V cells per field.  Results show that compared to RasG12V cells cultured alone, there is a 2-
fold increase in RasG12V cell number cultured with KO MEFs.  For RasG12V cells cultured with 
WT MEFs there is a 6.5 fold increase in RasG12V number compared to RasG12V alone and a 2.6-
fold increase above RasG12V cells co-cultured with Cav-1 null MEFs (Figure 28B).  As an 
alternative proliferative measurement, Ki67 positive RasG12V cells were quantified in the same 
way.  Neither WT nor Cav-1 KO MEFs stained positive for Ki67 (data not shown) as they were 
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growth arrested from serum starvation.  Results show RasG12V cells cultured with senescent WT
MEFs exhibit a 15-fold increase in the amount of Ki67 positive cells per field compared to
RasG12V only.  In contrast, RasG12V cells cultured with Cav-1 KO MEFs only had a 2-fold 
increase in Ki67 positive cells compared to RasG12V alone.  Comparison between WT and Cav-1 
KO co-cultures shows a 7.5 fold difference in Ki67 positive cells between these two populations 
(Figure 28C).  
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Figure 28.  Proliferation of transformed RasG12V fibroblasts is dependent upon Cav-1 expressing 
fibroblasts.  Wildtype (WT MEFs) and Cav-1 knockout (KO MEFs) mouse embryonic fibroblasts were normali
media.  The MEFs along w
senescent 
zed 
for cell number and plated into 10 cm dishes.  When cultures were approximately 50% confluent, MEFs were 
treated with 150 mM hydrogen peroxide for 2 hours, washed twice with 1X PBS and recovered for 4 days in normal 
ith RasG12V cells were serum starved for 3 days and co-cultured together by plating 
37,500 RasG12V cells onto the MEF lawns. Immunofluorescence was carried out by co-staining cultures with DAPI 
and Ki67.  Fluorescent secondary antibodies detected the Ki67.  A representation of the immunofluorescent staining 
is depicted in (A).  Quantification was conducted by counting the total number of RasG12V nuclei by DAPI staining, 
and positive Ki67 cells in 30 random fields (B and C).  Results are representative of 3 independent experiments and 
the values represent ± SEM *,#P<0.001. 
5.2.3 Cav-1 expressing senescent fibroblasts stimulate growth of MDA-MB-231 breast 
cancer cells in vitro 
MDA-MB-231 is a breast cancer cell line known to be stimulated by senescent fibroblasts 
(Krtolica and Campisi 2003; Liu and Hornsby 2007).  Co-culturing MDA-MB-231 cells with 
growth arrested Cav-1 deficient fibroblasts was done to determine whether the senescent 
fibroblasts’ antagonistic pleiotropic effect is dependent upon Cav-1.  Wildtype and Cav-1 
knockout mouse embryonic fibroblasts (MEFs) were treated the same way as in Figure 28.  After 
3 days of serum starvation MEFs and MDA-MB-231 cells were co-cultured together.  Cells were 
co-cultured by adding MDA-MB-231 cells to MEFs and allowing growth for 7 days.  DAPI 
staining was conducted to determine foci formation and quantification of MDA-MB-231 
colonies.  Figure 29A shows the number of foci with > 20 cells per foci. Results show that there 
is a 28% decrease in foci in breast cancer cells cultured with Cav-1 knockout MEFs compared to 
those co-cultured with WT MEFs.  Co-cultures were also stained with crystal violet to detect 
larger colonies of MDA-MB-231 cells (Figure 29B).  Results were obtained by counting the 
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number of colonies ≥0.3mm2 per cm2.  Crystal violet staining shows there is an ~ 250% 
reduction in foci with MDA-MB-231 cells cultured with Cav-1 null MEFs compared to WT.  
The MDA-MB-231 cells alone, WT MEFs alone, and Cav-1 KO MEFs alone did not produce 
colonies (Figure 29C). 
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 Figure 29.  Breast cancer cell proliferation is stimulated by Cav-1 expressing senescent fibroblasts.  Wildtype 
MB-231 cells and MEFs were co-c tured together by plating 37,500 (for 6 cm dish) or 112,500 (for a 10 cm dish) 
MDA-MB-231 cells onto the MEF lawns.  The cultures in 6 cm dishes were stained with DAPI and the number of 
connected regions of pixels with saturation greater than 0.2 on a [0, 1] scale. Only colonies with area greater than 32 
pixels, which corresponds to  ≥0.3mm  were counted (C).  
(WT MEFs) and Cav-1 knockout (KO MEFs) mouse embryonic fibroblasts were normalized for cell number and 
plated into 6 or 10 cm dishes.  When cultures were approximately 50% confluent, MEFs were treated with 150 mM 
hydrogen peroxide for 2 hours, washed twice with 1X PBS and recovered for 4 days in normal media.  The MEFs 
were serum starved for 3 days as well as the MDA-MB-231 which were supplemented with 5µg/mL insulin. MBA-
ul
MDA-MB-231 colonies containing ≥ 20 cells on the dish was quantified.  (A).  Co-cultures in 10 cm dishes were 
stained with crystal violet (0.1 gram per ml crystal violet in 70% ethanol) for 2 minutes followed by extensive 
washing with 1X PBS (B). Quantification of crystal violet staining was done by Matlab software which 
preprocessed the image by cropping the central area of each plate, converting to the HSV color space, and finding 
2
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5.2.4 Secreted factors mediate the ability of Cav-1 expressing senescent MEFs to 
stimulate the proliferation of NIH 3T3 RasG12V-transformed fibroblasts 
It has been shown that secreted factors, such as cytokines and matrix metalloproteinases, from 
stress induced senescent cells can change the stroma and microenvironment of a cell.  
Additionally, these factors can induce the growth of neoplastic epithelial cells (Krtolica and 
Campisi 2003; Liu and Hornsby 2007; Coppe, Boysen et al. 2008). Based on the co-culturing 
experiments, it was determined that wildtype senescent fibroblasts can induce proliferation of 
transformed epithelial and transformed fibroblast cells.  It is hypothesized that Cav-1 wildtype 
senescent cells may have a different secretion profile compared to Cav-1 null cells.  To test this 
hypothesis, wildtype and Cav-1 knockout mouse embryonic fibroblasts (MEFs) were treated 
with oxidative stress and recovered for 4 days.  The treated MEFs were serum starved for 3 days 
along with RasG12V cells.  Before co-culturing, conditioned media from MEFs was collected and 
MEFs were removed from culturing dishes by calcium chelation.  This did not disrupt the 
extracellular matrix (insoluble secreted factors).  Conditioned media was replaced back into its 
respective dishes and RasG12V cells were added to the plates.  Cells were permitted to grow for 7 
days and DAPI and Ki67 staining were conducted to quantify Ras cell proliferation due to 
secreted factors from the MEFs. DAPI staining shows secreted factors from senescent Cav-1 
expressing MEFs cause a 5-fold increase in the proliferation of Ras cells (Figure 30A).  This is 
decreased 2.5 fold in Cav-1 null MEFs.  Likewise, Ki67 staining shows an 8-fold increase in Ras 
cells entering mitosis when cultured in factors from WT MEFs compared to RasG12V cells in 
serum free media.  When comparing RasG12V cell growth from WT versus KO secreted factors 
G12Vthere is a 5.3-fold decrease in mitotic Ras  cells from KO cultures  (Figure 30B).  
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 oblasts.  Wildtype (WT MEFs) and Cav-1 knockout (KO MEFs) mouse embryonic 
fibroblasts were normalized for cell number and plated into 10 cm dishes.  When cultures were approximately 50% 
Figure 30.  Cav-1 expressing fibroblasts have a secretion profile that stimulates the growth of NIH 3T3 
RasG12V transformed fibr
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co t, MEFs were treated with 150 mM hydrogen peroxide for 2 hours, washed twice with 1X PBS and 
recovered for 4 days in normal media.  The MEFs along with RasG12Vcells were serum starved for 3 days.  Media 
 Ce
G12V
were cultured in the conditioned media and the extracellular matrix from the MEFs. To determine proliferation, 
seven days later cells were double stained with DAPI (A) and Ki67 (B).  Cells were quantified by counting the 
number of nuclei and Ki67 positive cells in 30 random fields from 2 independent experiments.  Values represent 
means ± SEM *,#P<0.001. 
G12V
G12V
nfluen
was collected off of the MEF cultures and saved while the cells were removed by mild calcium chelation from ll 
Dissociation Buffer in PBS (Gibco).  Media was replaced back onto the respective plates and 37,000 Ras cells 
5.2.5  The antagonistic pleiotropic effect of senescent fibroblasts on the 
proliferation of neoplastic cells in vivo is dependent upon Cav-1 
In vitro co-culturing of senescent Cav-1 wildtype and Cav-1 null fibroblasts demonstrated that 
Cav-1 expression was necessary for the antagonistic pleiotropic effect of senescent fibroblasts on 
neoplastic cells.  Co-cultures using oxidatively stressed and growth arrested Cav-1 knockout 
cells did not significantly induce proliferation of Ras  fibroblasts or breast cancer cells MDA-
MB-231.  Additionally, the soluble and insoluble factors secreted by the Cav-1 knockouts were 
not sufficient to generate growth of the Ras  cells.  In contrast, Cav-1 WT fibroblasts that 
have undergone SIPS stimulate the growth of RasG12V and MDA-MB-231 in vitro.  Likewise, 
secretion factor studies show that WT MEFs have a secretory profile that supports the growth of 
transformed cells.  This data supports the hypothesis that Cav-1 is necessary for the antagonistic 
pleiotropic effect of SIPS cells causing proliferation of neoplastic cells.  However, it is not 
known whether Cav-1 is necessary for the antagonistic pleiotropic effect of SIPS cells producing 
tumorigenesis in vivo. 
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 in vivo a 
tumo
G12V or 
ors were 
excised and the volum T or KO 
njected with 
MEFs and Ras G12V + WT 
MEFs had 47 mm .  Thus, Cav-1 
ore than 
e procedure 
elial breast cancer cells.  
en these epithelial 
cells were m e increased to 7 
mm3 rs extracted from 
231 alone and 3.5-fold larger than that of epithelial cells injected along with Cav-1 knockout 
MEFs (Figure 31C and D). 
To test whether Cav-1 is necessary for SIPS cells inducing tumorigenesis 
rigenesis assay was done in nude mice.  Cav-1 WT and KO MEFs were treated with 
hydrogen peroxide and allowed to recover for 7 days.  The MEFs were mixed with Ras
MDA-MB-231 cells and injected into 5-week old nu/nu mice.  After 4 weeks tum
e was determined.  Results show that mice injected either W
MEFs alone did not form tumors (data not shown).  However, data from mice i
G12V show that RasG12V alone had a tumor size of 18 mm3 whereas Ras
3 and RasG12V + KO MEFs exhibited a tumor volume of 16 mm3
expressing senescent fibroblasts stimulated tumor growth of RasG12V cells 2.25-fold m
Ras alone and 3 fold more than Cav-1 knockout MEFs (Figure 31A and B).  The sam
was carried out for tumorigenesis assays with MDA-MB-231 epith
MDA-MB-231 cells injected alone showed a tumor volume of 0.5 mm3.  Wh
ixed with hydrogen peroxide treated WT MEFs, the tumor volum
, and with treated KO MEFs it was found to be 2 mm3.  Hence, tumo
MDA-MB-231 cells co-injected with wildtype MEFs were 14-fold larger than that of MDA-MB-
 128 
  129 
 Figure 31.  Antagonistic pleiotropic effect of senescent fibroblasts is dependent upon Cav-1 in vivo.  Wildtype 
(WT) an
The following groups were in subcutaneously injected into the dorsal flap of nude (nu/nu) mice (5-6 weeks old from 
nly
2
shown in (B) and (D). Values in (B) represent means ± SEM. *, #P<0.01. Values in (D) represent means ± SEM. *, 
d Cav-1 knockout (KO) MEFs were treated with oxidative stress by exposure to 150 µM of hydrogen 
peroxide in the culturing media for 2 hours.  Cells were rinsed twice with 1X PBS and allowed to recover for 7 days.   
Charles Rivers Laboratories):  3.25 x105 RasG12V cells o , 3.25 x105 MDA-MB-231 cells only, 1 x 106 WT or KO 
MEFs only, 3.25 x105 RasG12V cells plus 1 x 106 WT or KO MEFs, and 3.25 x 105MDA-MB-231 cells plus 1 x 106 
WT or KO MEFs.  All cells were resuspended into a 100 μL volume.  Four weeks after the injection, tumors were 
excised and the x and y axes measured to determine tumor volume (size) according to the following formula: 
volume = 0.5 x width  x length. Representative images are shown in (A) and (C), quantification of tumor size is 
#P<0.001.  
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5.3 DISCUSSION 
Our studies identify Cav-1 as a novel gene fitting the evolutionary theory of antagonistic 
pleiotropy as it pertains to aging.  Cav-1 is a double-edged sword when it comes to aging and 
cancer: when expressed in cancer cells it acts as a tumor suppressor as evidenced its expression 
in RasG12V inducing SIPS.  On the other hand, Cav-1 is needed for premature senescence of 
fibroblasts, which can induce the growth of neoplastic cells. This work supports the hypothesis 
that Cav-1 is involved in senescent fibroblasts exhibiting antagonistic pleiotropy on neoplastic 
cells.  In vitro and in vivo studies show that Cav-1 expression is necessary for senescent 
fibroblasts and for their ability to stimulate hyperproliferation and tumorigenesis.  Fibroblasts 
were treated with hydrogen peroxide and all cells were starved in serum free media.  This was 
done to i) avoid influences of growth factors contained in the media, ii) arrest the Cav-1 null 
MEFs which would continue to grow after oxidative stress, and iii) arrest the transformed cells to 
observe growth caused by co-culturing.  In co-cultures and tumors using Cav-1 knockout MEFs, 
growth arrest of fibroblasts is not sufficient to cause hyperproliferation of transformed cells.   
Cav-1 is mediating the antagonistic pleiotropic effect of senescent fibroblasts. Fibroblasts 
must be senescent as growth arrest is not sufficient for senescence dependent antagonistic 
pleiotropy in the Cav-1 knockout MEFs.  RasG12V and MDA-MB-231 cells co-cultured with KO 
cells had in vivo tumor growth 3-fold and 14-fold less than wildtype. Data in Chapter 4 support 
that Cav-1 is necessary for SIPS triggered by oxidative stress in fibroblasts.  Upon oxidative 
stress from hydrogen peroxide treatment, Cav-1 sequesters p53’s negative regulator, MDM2, 
which allows p53 to become active stimulating signaling pathways leading to SIPS.  Thus, Cav-1 
is necessary to potentiate the SIPS cell program.   
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Senescent cells possess an altered secretory profile.  Interestingly, the prematurely 
senescent fibroblast secretion profile is similar to the proliferative cancer associated fibroblasts 
and how they stimulate growth of transformed epithelial cells (Fusenig and Boukamp 1998; 
Olumi,
cancer tumors is still unknown.  From our in vivo experiments it would seem that senescent 
 Grossfeld et al. 1999; Mercier, Casimiro et al. 2008).  The reason senescent fibroblasts 
express this phenotype may be to sustain the tissue and give a growth advantage to the non-
senescent fibroblasts in the area.  However, an accumulation of senescent fibroblasts with age 
also illustrates the antagonistic pleiotropy of the prematurely senescent cells as it promotes the 
growth of mutated epithelial cells (Campisi 2003).  Senescent fibroblasts are found to secrete 
factors related to proliferation and changing the microenvironment such as: VEGF, (Coppe, 
Kauser et al. 2006), matrix metalloproteases (Dilley, Bowden et al. 2003; Liu and Hornsby 
2007), chemokines (Acosta, O'Loghlen et al. 2008), TGF-ß1 (Frippiat, Chen et al. 2001), 
fibronectin (Chainiaux, Magalhaes et al. 2002) and IGFBP4 (Coppe, Boysen et al. 2008).  
Secretion studies show that the factors necessary to cause hyperproliferation are exclusive to 
Cav-1 expressing senescent fibroblasts.  Cav-1 is necessary to trigger the senescent phenotype, 
which initiates the different expression profile.  Whether Cav-1 has additional influence has yet 
to be elucidated.   
 Cancer associated fibroblasts (CAFs) have recently been shown to exhibit decreased Cav-
1 expression in breast cancer. These data initially appear to be in opposition to our findings, 
which say an upregulation of Cav-1 followed by SIPS can induce proliferation of breast cancer 
cells.  However, in this study the CAFs were isolated by their proliferation capabilities (Mercier, 
Casimiro et al. 2008), which completely excluded senescent fibroblasts and only focuses on non-
senescent proliferating fibroblasts.  Thus, the contribution of senescent fibroblasts in breast 
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fibrobla
nd hydrogen peroxide), which leads to oxidative stress and 
oblasts display altered expression of genes involved in growth arrest, 
stress response, matrix metalloproteases and senescence (Borlon, Debacq-Chainiaux et al. 2007). 
sts are involved early in tumorgenesis, as neoplastic cells dilute the senescent cells very 
quickly.  Therefore, the senescent cells and the factors they secrete may be needed at the onset of 
tumor growth to give the neoplastic cells a growth advantage. 
Much work on antagonistic pleiotropy of senescent fibroblasts has been done in vitro, but 
there is also evidence of this in vivo. The disease model of psoriasis is an illustration of 
antagonistic pleiotropy in the realm of premature senescence.  PUVA treatment is used to treat a 
wide variety of skin ailments including psoriasis (Parrish, Fitzpatrick et al. 1974; Wolff, 
Gschnait et al. 1977; Ma, Wlaschek et al. 2002).  The therapy utilizes the photosensitizer 8-
methoxypsoralen and UVA (320—400 nm) irradiation to induce the formation of ROS (such as 
singlet oxygen, superoxide anion a
DNA damage (Pathak and Joshi 1983; Gasparro, Felli et al. 1997; Gasparro, Liao et al. 1998).  
Among the list of side effects for PUVA treatment is premature aging of the skin similar to other 
types of photodamage.  For example, PUVA treatment causes thinning of the skin in psoriasis 
patients compared to age matched controls (Sator, Schmidt et al. 2002).  In concurrence with 
these findings, PUVA induces SIPS in human dermal fibroblasts (Herrmann, Brenneisen et al. 
1998; Hovest, Bruggenolte et al. 2006) evidenced by upregulated matrix metalloproteases, 
decreased cumulative population doublings, a large and squamous morphology and positive SA-
β-galactosidase activity – all hallmarks of SIPS.  Additionally, PUVA-stimulated SIPS is 
mediated in part by hydrogen peroxide generation (Herrmann, Brenneisen et al. 1998), a reactive 
signaling mediator, which is regularly used to induce SIPS.  Gene expression profiles of PUVA 
treatment on human fibr
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PUVA treated psoriasis patients have high incidences of epithelial skin carcinomas (S
and Lunder 1998).  However, none of the tumors are derived from fibroblasts (Ma, Homm
al. 2003).  It is hypothesized that this is antagonistic pleiotropy (Campisi 2005).  It could be that 
upon PUVA treatment fibroblasts undergo SIPS, and overtime the MMPs and cytokines they 
secrete cause preneoplastic cells in the surrounding environment to become carcinogenic.   W
the psoriatic plaque environment is seemingly prime to induce carcinogenesis, lesions do not 
generate in the plaque but in adjacent areas.  The keratinocytes associated with the plaques
senescent and tumor resistant.  Thus, this medical paradox is explained by senescent cells having 
or suppressor mechanism for themselves while activating growth of neighboring cells 
(Nickoloff 2001; Nickoloff 2004). 
tern 
el et 
hile 
 are 
a tum
Cav-1 dependent SIPS from an oxidative stressor, can cause the proliferation of mutated 
determines that Cav-1 is necessary to induce SIPS by oxidative stress in fibroblasts, as supported 
by the unique mechanism that upon oxidative stress Cav-1 sequesters MDM2, thereby allowing 
for p53 activation and SIPS.  While this is a tumor suppressing mechanism for the fibroblast, the 
Cav-1 dependent senescence can cause antagonistic pleiotropy and induce proliferation of 
initiated epithelial cells. 
 In conclusion we have found a novel mechanism in which Cav-1 plays two seemingly 
opposite roles when it comes to aging and cancer.  When Cav-1 is re-expressed in cancer cells 
where the gene is down-regulated, Cav-1 shows tumor suppressor properties by triggering a 
“senescent switch” which ceases the growth of the cell.  In contrast, fibroblasts that undergo 
epithelial cells.  Thus, Cav-1 acts as a tumor promoter to adjacent cells (Figure 32).  Our work 
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 Figure 32.  Schematic diagram of the diverse roles of Cav-1, illustrating how Cav-1 demonstrates tumor 
suppressor activities.  On the single cell level, Cav-1 can cause senescence in transformed cells.  It is also needed 
by fibroblasts damaged by oxidative stress to undergo senescence.  Both of these instances cause diminished growth 
in the individual cell.  On the tissue level, an accumulation of senescent cells can lead to tumor promotion.  The 
change in the secretory profile of senescent cells contributes to changes in the microenvironment that have pro-
tumorigenic effects on mutated cells in the surrounding area.  Since oxidative stress induced SIPS is dependent upon 
Cav-1 the downstream effect of antagonistic pleiotropy is also dependent upon the protein. 
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6.0 CONCLUSION 
s of the cornea (Dawson, O'Brien et al. 2006).  Psoriatic plaques 
contain senescent keratinocytes which induce le
arthritic joints, and both benign and preneoplastic hyperproliferative lesions in prostrate and liver 
 
We have found that oxidative stress triggers a Cav-1 mediated signaling pathway, which induces 
SIPS.  Upon oxidative stress cellular changes activate p38MAPK, resulting in activation of the 
transcription factor Sp1.  Sp1 binds to 2 GC-boxes in the Cav-1 promoter upregulating the 
protein.  Cav-1 sequesters MDM2, a negative regulator of p53, so that p53 degradation is halted 
and it is active to up-regulate its downstream target p21WAF/CIP1 leading to SIPS.  Additionally, 
Cav-1 exhibits tumor suppressor activities as it works as a senescence switch.  Interestingly, 
Cav-1 functions to induce cancer by its antagonistic pleiotropic effect in senescent fibroblasts 
secreting factors, which lead to proliferation of neighboring neoplastic cells. 
Biomedical science is uncovering many SIPS occurrences in vivo.  LASIK eye surgery 
triggers senescence in keratocyte
sions adjacent to the plaques (Nickoloff 2004). 
Inflammatory factors of chronic wounds trigger SIPS in surrounding fibroblasts affecting the 
ability of the wounds to heal (Harding, Moore et al. 2005),  and senescence in kidney epithelial 
cells may affect organ transplantation success (Famulski and Halloran 2005).  Current 
understanding of the SIPS phenomena does not explain what is occurring at the cellular level in 
these examples nor how to minimize the potential detrimental side effects of SIPS.    Senescent 
cells are located at the sites of age-related diseases such as atherosclerotic lesions, skin ulcers, 
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(Campisi 2005).  As the age of our population increases age-related diseases, revealing the 
mechanisms leading to cellular senescence in vivo becomes increasingly necessary for improving 
public health. 
suppresso arcinogenic 
tumo ce SIPS (LASIK, 
psoralen plus UVA, echanism 
of how SIPS occurs will provide inf
be detrimental to the patient. Because SIPS is exogenously triggered, its reasoned that SIPS is a 
suppressing mechanism). 
eutic target for aging and 
cancer. Managing Cav-1 expression is a delicate balancing act (Figure 33). Cav-1 can have 
tumorig
Understanding SIPS and aging is significant for improving health.  First, SIPS is a tumor 
r for the cells that undergo growth arrest, which is a positive effect from a c
standpoint.  However, SIPS cells can induce neighboring preneoplastic cells to become 
rigenic, which is deleterious.  Since many medical treatments actually indu
 and chemotherapy for malignancies) research on the underlying m
ormation on preventing SIPS from occurring when it could 
drug-responsive cellular program, which can be exploited for therapeutic treatments (Nickoloff 
2004).  Understanding the mechanisms of these phenomenon will aid in the creation of better 
interventions and therapies to slow ageing due to oxidative damage, and will allow the 
manipulation of the system by encouraging aging when it would be beneficial, (e.g. as a tumor 
The data herein identify the protein Cav-1 as a key therap
enic and tumor suppressor activities depending on the cell type and environment, 
demonstrating that it is clearly an antagonistic pleiotropic gene. Decreasing Cav-1 in cells would 
have an anti-aging effect, as cells would not respond to oxidative stress with SIPS and would 
either continue proliferation, or undergo apoptosis.  However, in transformed cells, increasing 
Cav-1 would have the beneficial effect of inducing growth arrest and SIPS to slow the growth of 
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the neoplasm.  The CSD would be sufficient to induce SIPS and further work using the Cavtratin 
peptide could determine whether the CSD could induce SIPS in tumor cells in vivo. 
 
Figure 33.  Schematic depicting the balancing act of managing Cav-1 as a potential therapeutic target in 
aging and cancer.  Exogenous signals cause DNA damage, which cause cells to either senesce or become 
cancerous.  The expression of Cav-1 in these cells is a delicate balancing act.  Cav-1 exhibits tumor suppressor 
properties, which is a contributor to the aging phenotype.  However, the absence of Cav-1 can also have deleterious 
effects, as it is downregulated in many tumors.  Cav-1 is now identified as an antagonistic pleiotropic gene.  
Therefore, the system is complicated by the fact in some instances Cav-1 has positive attributes where it mediates 
senescence to allow the organism to avoid cancer.   However, senescent fibroblasts can induce the proliferation of 
surrounding mutated epithelial cells giving them the push they need to proliferate.   
 
In terms of treating cancer, the identification of Cav-1 as a mediator of antagonistic 
pleiotropy pertaining to SIPS, sheds light on a new way to target therapeutics.  Fibroblasts that 
contain Cav-1 respond to cellular damage by undergoing SIPS, which is a tumor suppressing 
mechanism for these cells.  However, the detrimental effect these fibroblasts have on their 
microenvironment must be addressed.  Cav-1 is necessary for cells to undergo tumor suppressing 
SIPS, however, mutated epithelial cells in the area will respond to the secreted MMPs, 
chemokines, and growth factors by proliferating.  Therefore, Cav-1 should not be targeted in 
cancer, as it is performing its tumor suppressing duty, but the secretion profile it creates in the 
senescent cells should be examined.  If there are ways of inhibiting these factors (e.g. by 
inhibitory antibodies or small molecules) it is plausible to allow Cav-1’s tumor suppressing 
properties and curtail its antagonistic pleiotropic effects. 
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